Inspira Technologies Overview
Inspira Technologies is a medical device company specializing in respiratory care solutions. The company’s flagship product, the Inspira ART system, utilizes a hemo-protective flow approach designed to rebalance oxygen saturation levels while patients are awake and breathing spontaneously. The Inspira ART system acts as an artificial lung to rebalance patients’ oxygen saturation levels in minutes. By adding oxygen to the blood and removing CO2 from the blood, the Inspira ART system has the potential to minimize the need for mechanical ventilation.
Cumulative Funding Raised Over Time ($)
$1.6MApr 2024
$4.8MDec 2024
$5.7MMar 2021
Latest News
growth-positive
Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem
Inspira Technologies has announced a strategic collaboration with Bites Learning Ltd., a leader in AI-based digital training solutions. This partnership will integrate Bites AI-powered platform into Inspiras ecosystem, including the INSPIRA ART100 cardiopulmonary support system and the HYLA blood sensor. The collaboration aims to enhance training, onboarding, and operational performance for hospitals and distributors globally. Key benefits include AI-driven training modules, personalized knowledge feeds, and data-driven analytics. The partnership also includes joint marketing and innovation efforts, with provisions for future strategic transactions. This collaboration is expected to expand adoption, improve operational consistency, and drive shareholder value.
PartnersCustomers
growth-positive
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from the healthcare sector, including roles at Johnson & Johnson. Sivan Matza joins the board as an independent director, succeeding Limor Rosen. Matzas background in international finance and regulation is expected to enhance Inspiras governance framework. These appointments are strategic moves to accelerate Inspiras commercial expansion and adoption of its technologies in hospitals worldwide. The company expressed gratitude to Limor Rosen for her contributions.
Management Changes
growth-positive
Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from Johnson & Johnson and other med-tech firms. Sivan Matza joins the board as an independent director, leveraging her background in global finance and regulation. These appointments aim to enhance Inspiras sales strategy and hospital adoption initiatives, positioning the company for its next phase of growth. The company also acknowledged the contributions of Limor Rosen, who is stepping down from the board.
Management Changes
growth-positive
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update
Inspira Technologies has transitioned from a development-stage company to commercial execution, achieving significant milestones in the first half of 2025. The company secured $49.5 million in binding purchase orders for its ART100 system, with orders from a national ministry of health in Africa. Inspiras HYLA blood sensor achieved 97.35% accuracy, advancing towards FDA submission. The company also received U.S. patent approval for its ART500 core technology and engaged a strategic consulting firm to guide growth initiatives. Inspiras technology is now used in leading U.S. hospitals, including for lung transplant procedures, and aims for a $70 million revenue run rate in 2026.
Product StageCustomersFDA approved/pending approvalPartners
growth-positive
All You Need to Know About Inspira Technologies OXY (IINN) Rating Upgrade to Buy
Inspira Technologies OXY B.H.N. Ltd. has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates. This upgrade reflects an upward trend in earnings estimates, which is a significant factor influencing stock prices. The Zacks rating system, which focuses on changes in earnings estimates, is highly regarded for its ability to predict near-term stock price movements. The upgrade suggests an improvement in Inspira Technologies underlying business, which could lead to increased stock prices as investors recognize the companys potential. The Zacks Rank system has a strong track record, with top-ranked stocks historically generating substantial returns.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $21.69M |
| Last funding | $3.2M |
| Stage | Public |
| Rounds | 4 |
| Investors | 1 |
Team Members
10
Employees: 11-50
Web & Social Links
| Website | inspira-technologies.com/ |
| Careers | Careers page |
Locations
Ha-Tidhar St 2, Ra'anana, Israel
Photos & Videos
2 item(s)
Inspira Technologies Business
Business models
B2G, B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesLife SupportTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
SensingBiometricsTags (9)
medical-devicespatent-pendingclinicsminimally-invasivehospitalstreatmentsrespiratorypulmonarymedical-technologiesGeographic Markets
GlobalInspira Technologies Financials
$21.69M
Total funding
Undisclosed
Capital raised
$3.2M
Last funding
Public
Funding stage
4
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$1.6MApr 2024
$4.8MDec 2024
$5.7MMar 2021
Private Equity Funding
PIPE
Dec 2024
$3.2M
PIPE
Apr 2024
$1.65M
A Round
Mar 2021
$840K
Together We Invest
Public Offering / Exit
POEvent
Jul 2021
Undisclosed
Inspira Technologies Lifecycle
Cumulative Funding Raised Over Time
$1.6MApr 2024
$4.8MDec 2024
$5.7MMar 2021
All Events
PIPE
Dec 2024
$3.2M
PIPE
Apr 2024
$1.65M
A Round
Mar 2021
$840K
Together We Invest
POEvent
Jul 2021
Undisclosed
Inspira Technologies News
170 articles
growth-positive
Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem
Inspira Technologies has announced a strategic collaboration with Bites Learning Ltd., a leader in AI-based digital training solutions. This partnership will integrate Bites AI-powered platform into Inspiras ecosystem, including the INSPIRA ART100 cardiopulmonary support system and the HYLA blood sensor. The collaboration aims to enhance training, onboarding, and operational performance for hospitals and distributors globally. Key benefits include AI-driven training modules, personalized knowledge feeds, and data-driven analytics. The partnership also includes joint marketing and innovation efforts, with provisions for future strategic transactions. This collaboration is expected to expand adoption, improve operational consistency, and drive shareholder value.
PartnersCustomers
growth-positive
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from the healthcare sector, including roles at Johnson & Johnson. Sivan Matza joins the board as an independent director, succeeding Limor Rosen. Matzas background in international finance and regulation is expected to enhance Inspiras governance framework. These appointments are strategic moves to accelerate Inspiras commercial expansion and adoption of its technologies in hospitals worldwide. The company expressed gratitude to Limor Rosen for her contributions.
Management Changes
growth-positive
Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm
Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from Johnson & Johnson and other med-tech firms. Sivan Matza joins the board as an independent director, leveraging her background in global finance and regulation. These appointments aim to enhance Inspiras sales strategy and hospital adoption initiatives, positioning the company for its next phase of growth. The company also acknowledged the contributions of Limor Rosen, who is stepping down from the board.
Management Changes
growth-positive
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update
Inspira Technologies has transitioned from a development-stage company to commercial execution, achieving significant milestones in the first half of 2025. The company secured $49.5 million in binding purchase orders for its ART100 system, with orders from a national ministry of health in Africa. Inspiras HYLA blood sensor achieved 97.35% accuracy, advancing towards FDA submission. The company also received U.S. patent approval for its ART500 core technology and engaged a strategic consulting firm to guide growth initiatives. Inspiras technology is now used in leading U.S. hospitals, including for lung transplant procedures, and aims for a $70 million revenue run rate in 2026.
Product StageCustomersFDA approved/pending approvalPartners
growth-positive
All You Need to Know About Inspira Technologies OXY (IINN) Rating Upgrade to Buy
Inspira Technologies OXY B.H.N. Ltd. has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates. This upgrade reflects an upward trend in earnings estimates, which is a significant factor influencing stock prices. The Zacks rating system, which focuses on changes in earnings estimates, is highly regarded for its ability to predict near-term stock price movements. The upgrade suggests an improvement in Inspira Technologies underlying business, which could lead to increased stock prices as investors recognize the companys potential. The Zacks Rank system has a strong track record, with top-ranked stocks historically generating substantial returns.
growth-positive
Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed
Inspira Technologies, a leader in life-support and diagnostic technologies, is set to present its HYLA blood sensor at the U.S. ELSO Annual Conference in Washington, D.C. The HYLA sensor, which has demonstrated 97.35% accuracy, will be showcased to the global medical community, marking a significant step towards commercialization and strategic partnerships. The company will also present its FDA-cleared ART100 system, highlighting its comprehensive platform of advanced life-support solutions. Inspira Technologies is positioned as an attractive platform within the MedTech landscape, with multiple cleared products and a focus on strategic partnerships and commercialization.
Product StagePartners
growth-positive
Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance
Inspira Technologies announced significant advancements in its HYLA blood sensor, achieving 97.35% accuracy in performance testing. This development supports its upcoming FDA submission, marking a crucial step towards regulatory approval in the U.S. and Europe. The HYLA sensor offers continuous, non-invasive blood monitoring, providing real-time data crucial for critical care. It is designed to integrate with Inspiras ART device line and as a standalone product, targeting the broader disposables market. The company is positioned as a leader in life-support and MedTech, with FDA-cleared products and a focus on innovation. Inspiras CEO highlighted the sensors potential to revolutionize patient monitoring in operating rooms and critical care settings.
Product StageFDA approved/pending approval
growth-positive
When Will Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Become Profitable?
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, is focused on developing life support technologies for acute respiratory failure. Despite reporting a loss of US$11 million for the financial year ending December 31, 2024, analysts are optimistic about the companys future. They predict that Inspira will achieve profitability by 2026, with an expected profit of US$4.4 million. The company is currently in a growth phase, requiring an average annual growth rate of 87% to meet these expectations. Notably, Inspira operates without debt, relying solely on shareholder funding, which reduces investment risk. The company is involved in research and development and is leveraging AI technology to enhance its healthcare solutions.
growth-positive
Top U.S. Honor Roll Hospital Expands Use of INSPIRA™ ART100 System to Lung Transplant Procedures
Inspira Technologies announced that a top U.S. hospital has expanded its clinical use of the INSPIRA ART100 system to include lung transplantation procedures. This expansion is seen as a significant endorsement of the ART100 systems performance and clinical value, particularly in complex surgical settings. The ART100 system, which is FDA-cleared for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., is part of Inspiras broader strategy to establish itself as a leader in advanced respiratory support. The companys recent multi-million dollar government orders and strategic operational shifts highlight its growing commercial momentum and alignment with long-term industry trends.
CustomersProduct Stage
growth-positive
Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market
Inspira Technologies has received U.S. Patent approval for its low flow rates extracorporeal oxygenation system, a core technology of the ART500 device. This patent strengthens Inspiras intellectual property portfolio and positions the company to penetrate the $20 billion market for advanced respiratory support. The ART500 system is designed to provide oxygenation at low flow rates, targeting patients who require respiratory support but are not sick enough for traditional ECMO systems. This approval provides a competitive advantage and aligns with Inspiras growth strategy. The company is also pursuing additional patents globally and has FDA approval for its ART100 system, which serves as a foundation for the ART500 development.
Product StageFDA approved/pending approval
growth-positive
Inspira Secures $27 Million Government Binding Purchase Order for ART100 Systems with Full Payment in 2025
Inspira Technologies announced a $27 million binding purchase order from a national ministry of health in Africa for its FDA-cleared ART100 systems. This order, secured through an exclusive distribution partner, marks a significant strategic breakthrough for the company, accelerating revenue and validating its commercial model. The ART100 system, proven in Tier-1 hospitals in the U.S., will be deployed nationwide in Africa, reinforcing emergency and critical care infrastructure. This order is part of Inspiras broader commercial strategy, with total secured orders for 2025 reaching $49.5 million. The company is a commercial-stage medical device firm specializing in advanced respiratory support and blood monitoring solutions.
CustomersPartners
growth-positive
Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years
Inspira Technologies, a commercial-stage medical device company, has filed a shelf registration statement with the U.S. SEC as part of a routine renewal process. The company specializes in advanced respiratory support and blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. Inspira is also developing the INSPIRA ART500 and advancing its HYLA blood sensor platform. The company is strategically aligning with industry trends, potentially positioning itself for future partnerships.
Product StageFDA approved/pending approval
growth-positive
Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives
Inspira Technologies, a leader in life-support and diagnostic technologies, has engaged a consulting firm to accelerate its strategic expansion and partner engagement. The firm will help Inspira execute high-value transactions and commercial growth initiatives. Recent developments include major purchase orders, strategic frameworks with government health authorities, and clinical integration of the ART100 system in U.S. hospitals. These efforts aim to scale Inspiras commercial platform and enhance its position in the medtech ecosystem. The company is also advancing its INSPIRA ART500 system and the HYLA blood sensor platform. Inspiras FDA-cleared ART100 system is approved for specific medical procedures, and the company is poised for significant growth in 2025.
PartnersCustomersProduct Stage
growth-positive
Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement
Inspira Technologies has regained compliance with Nasdaqs minimum bid price requirement, reflecting market confidence in its strategic direction. The company is advancing its government-focused strategy, following successful talks and a $22.5 million purchase order. Inspiras ART100 system, cleared by the FDA for cardiopulmonary bypass in the U.S., is part of its broader product portfolio, including the next-generation ART500 and the HYLA blood sensor platform. These developments position Inspira as a significant player in the life-support and MedTech landscape, with a focus on global distribution and strategic partnerships.
Product StageCustomersPartnersInvestment
growth-positive
Inspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100
Inspira Technologies has announced a significant milestone in its strategic discussions with a government health authority outside the United States. The company has established a definitive pathway for the nationwide adoption of its ART100 system, which is clinically validated and field-proven. This development is expected to accelerate the integration of the ART100 into the national emergency infrastructure and create a foundation for a global distribution and manufacturing hub. The ART100 system is FDA-cleared for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. Inspira Technologies is positioning itself as a key player in the life-support and MedTech landscape, with a focus on global expansion and strategic partnerships.
PartnersCustomers
growth-positive
Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework
Inspira Technologies, a commercial-stage medical device company, is in advanced discussions with a government health authority outside the U.S. to integrate its FDA-cleared ART100 system into national emergency infrastructure and establish a global distribution framework. This strategic collaboration aims to enhance national emergency readiness and maximize the profitability of a $22.5 million purchase order. The ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. Inspira Technologies is also developing the INSPIRA ART500 system and advancing its HYLA blood sensor platform. These developments signal a shift towards global partnerships and increased recognition of the ART100 as a vital tool for national preparedness.
CustomersPartners
growth-positive
Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase
Inspira Technologies has secured a $22.5 million purchase order for its FDA-cleared ART100 system, marking a significant commercial milestone. This order, placed by a private company outside the U.S., signifies Inspiras transition into full-scale revenue generation. The ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures internationally. Inspira is in advanced negotiations with additional healthcare companies and governmental institutions, supporting its global commercial expansion strategy. The company is scaling its commercial infrastructure and advancing its product pipeline, including the development of the INSPIRA ART500 and the HYLA blood sensor platform. Inspiras strategic moves align with long-term industry trends, positioning it as a key player in the life-support and MedTech sectors.
CustomersProduct Stage
growth-positive
Inspira Technologies says ART100 in use at Tier-1 U.S. hospitals
Inspira Technologies has announced that its FDA-cleared ART100 system is gaining traction in the market, marking a significant milestone in its commercialization efforts. The system has been successfully integrated into clinical workflows at top-tier U.S. hospitals, demonstrating its potential to support critically ill patients. This success has sparked interest from additional U.S. and international healthcare institutions and governmental bodies. The company is in commercial discussions with various stakeholders and is scaling up its operational capabilities to meet the anticipated demand for the ART100 system. This development positions Inspira Technologies as a leader in the life-saving technology market.
Product StageCustomers
growth-positive
Inspira’s ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions
Inspira Technologies announced the successful adoption and integration of its FDA-cleared ART100 system into clinical workflows at leading U.S. hospitals, marking a significant milestone in its commercialization efforts. The systems use in real-world settings has generated increased interest from additional healthcare institutions and governmental authorities, both domestically and internationally. Inspira is scaling up operations to meet anticipated demand and is engaged in advanced negotiations with a European government authority. The company is also developing the INSPIRA ART500, a next-generation system, and advancing its HYLA blood sensor platform. These developments position Inspira as a key player in the life-support and MedTech market.
Product StageCustomersFDA approved/pending approval
growth-positive
Inspira Technologies scales up ART100 production capabilities
Inspira Technologies has scaled up production of its FDA-cleared INSPIRA ART100 system to meet anticipated demand from a European governmental authority. The company is in advanced procurement negotiations and aims to fulfill near-term delivery needs. The ART100 system is already in use in U.S. clinical settings and is gaining recognition for its reliability in critical care and emergency preparedness. Additionally, Inspira Technologies is undergoing a global commercial rollout of the ART100 system and has restructured its executive team for strategic alignment.
Product StageCustomersManagement Changes
growth-positive
Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
Inspira Technologies has announced an expansion of its production capabilities for the FDA-cleared INSPIRA ART100 system, anticipating increased demand from a European governmental authority. The company is in advanced procurement negotiations and aims to meet near-term delivery needs. The ART100 system is already in use in the U.S. and is gaining traction for critical care and emergency preparedness. Inspira is also developing the ART500 and HYLA blood sensor, positioning itself as a strategic public health supplier. The company is focused on fast-tracking revenue generation and aligning with long-term industry trends.
Product StageCustomersFDA approved/pending approval
growth-positive
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
Inspira Technologies, a medical device company, is scaling up production of its FDA-cleared INSPIRA ART100 system to meet anticipated demand from a European governmental authority. This strategic move is part of the companys global rollout strategy and aims to fast-track revenue generation. The ART100 system, already in clinical use in the U.S., is gaining traction for critical care and emergency preparedness. Inspira is also developing next-generation platforms, including the ART500 and the HYLA blood sensor. The company is positioning itself as a strategic public health supplier, leveraging its FDA-cleared products and growing IP portfolio to align with industry trends and potential partnerships.
Product StageCustomersFDA approved/pending approval
growth-positive
Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System
Inspira Technologies is accelerating the commercialization of its FDA-cleared INSPIRA ART100 system following successful clinical implementations in the U.S. The company is engaged in advanced sales discussions with governmental health departments and private organizations, aiming to begin deliveries in the second half of 2025. Inspira is focusing on near-term revenue activities from ART100 while continuing to develop its innovation pipeline, including the next-generation ART500 and the HYLA blood sensor. The companys expansion efforts align with the growing global demand for scalable respiratory solutions, positioning it as a strategic platform for public health initiatives and potential partnerships.
Product StageCustomersFDA approved/pending approval
growth-positive
Inspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives
Inspira Technologies announced a significant change in its executive structure as Co-Founder and President Joe Hayon steps down from his operational role but remains on the Board. This move is part of a strategic alignment to enhance operational clarity and flexibility. The company, known for its advanced respiratory support and diagnostic systems, continues to focus on innovation and long-term value creation. Inspiras FDA-cleared INSPIRA ART100 system is approved for specific medical procedures, and the company is developing the next-generation INSPIRA ART500 system. The leadership transition is not expected to affect ongoing operations or R&D timelines, positioning Inspira to better navigate the evolving healthcare landscape.
Management Changes
growth-positive
INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients
Inspira Technologies announced that its INSPIRA ART100 system has been approved for clinical validation by Israels largest healthcare provider. This system, which has already received FDA 510(k) clearance, will be used in organ transplant procedures to maintain organ viability through advanced blood oxygenation. The validation process will provide valuable insights for the development of Inspiras flagship INSPIRA ART500 system, aimed at revolutionizing respiratory care. The deployment of the ART100 system in a renowned medical center signifies a significant interest in Inspiras technology from leading medical institutions.
Product StageCustomers
growth-positive
Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing
Inspira Technologies announced a significant milestone in the in-vivo testing of its VORTX technology, which aims to revolutionize blood oxygenation by reducing trauma associated with conventional methods. The testing, conducted on an 80 kg swine, achieved over 99% gas exchange, confirming the technologys potential. This development is part of an initiative funded by the Israel Innovation Authority. Inspiras VORTX technology is designed to integrate into its pipeline, including the INSPIRA ART500, to provide advanced respiratory care. The company plans further evaluation and refinement of the technology. Inspiras INSPIRA ART100 system has FDA clearance for specific procedures, while other products are still in development.
Product StageFDA approved/pending approval
growth-positive
Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems
Inspira Technologies OXY B.H.N. Ltd. has achieved a significant milestone by generating its initial revenues from the deployment of its FDA-cleared INSPIRA ART100 systems in a leading U.S. healthcare facility. The company has received payment from its U.S. distributor, Glo-Med Networks Inc., for the delivery of these systems, marking a transformative step in its U.S. expansion strategy. The INSPIRA ART100, designed for cardiopulmonary bypass procedures, is part of Inspiras broader plan to revolutionize the mechanical ventilation market with its upcoming INSPIRA ART500 system. This achievement underscores Inspiras innovative approach and its ability to collaborate with top-tier medical institutions.
Product StageCustomersPartners
growth-positive
Inspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center
Inspira Technologies announced the successful first clinical use of its FDA-cleared INSPIRA ART100 system, marking a significant milestone in the companys development of life-support and diagnostic technologies. The procedure, performed at Westchester Medical Center, demonstrated the systems effectiveness in providing heart and lung support. The positive outcome has set the stage for broader adoption across hospitals, facilitated by Glo-Med Networks Inc., Inspiras U.S. distributor. The company aims to expand clinical use and advance critical care solutions globally. Inspiras pipeline products, including the INSPIRA ART500 and HYLA blood sensor, are still in development and have not yet received regulatory approval.
Product StageCustomersPartners
growth-positive
Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital
Inspira Technologies OXY B.H.N. Ltd. has successfully deployed its FDA-cleared INSPIRA ART100 system at a premier hospital in New York, marking a significant milestone in its deployment plan. The system is set for clinical use in cardiopulmonary bypass procedures, with feedback expected soon. This deployment is part of Inspiras broader strategy to revolutionize the $19 billion mechanical ventilation market with its INSPIRA ART500 system. The company aims to replace a significant portion of the estimated 100,000 ventilators in the U.S. with its innovative technology. The successful installation and training program at the hospital are seen as transformative for Inspira, enhancing its commercial presence in the U.S. healthcare market.
Product StageCustomers
growth-positive
Market Alert: Inspira Technologies' Respiratory Tech Could Transform $19B Ventilator Market Amid Major Wave of Multi Billion Dollar Medtech Acquisitions
Inspira Technologies is making significant strides in the medtech industry with the deployment of its FDA-cleared INSPIRA ART100 system at a top New York hospital. This marks a major commercialization milestone for the company, which is also advancing its flagship INSPIRA ART500 system. The ART500, equipped with AI technology, targets 20 million annual respiratory patients and aims to provide respiratory support without intubation. Inspiras HYLA blood sensor has achieved 96% accuracy in clinical trials, showcasing its potential in the blood gas analyzer market. The companys innovative approach is highlighted amid a backdrop of significant medtech acquisitions, positioning Inspira as a key player in the evolving respiratory care sector.
Product StageCustomers
growth-positive
Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego
Inspira Technologies OXY B.H.N. Ltd. is set to showcase its FDA-cleared INSPIRA ART100 cardiopulmonary bypass technology at the American Society of Extracorporeal Technology (AmSECT) 63rd International Conference in March 2025. The event will take place at the Loews Coronado Bay Resort in San Diego, California. The INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024, represents a significant advancement in extracorporeal circulation technology. The companys distributor, Glo-Med Networks Inc., will present the technology at the conference. Inspira Technologies is also developing other innovative respiratory support and diagnostic technologies, including the INSPIRA ART500 system and HYLA blood sensor, which are still in development and awaiting regulatory approval.
Product StagePartners
growth-positive
PESG Report: Inspira Technologies' AI-Powered Respiratory System Could Revolutionize Care for 20 Million Annual ICU Patients in Combined $25+ Billion Market
Inspira Technologies has demonstrated significant progress in its clinical trials, achieving 96% accuracy with its AI-powered HYLA blood sensor. This positions the company to target the $5.7 billion blood gas analyzer market and the $19 billion mechanical ventilation market. The companys FDA-cleared ART100 system is already in use in U.S. hospitals, and the HYLA systems FDA submission is planned for the second half of 2025. Inspira is accelerating the development of its flagship INSPIRA ART500 system, which aims to transform respiratory care by offering a less invasive alternative to traditional mechanical ventilation. This approach could significantly improve patient outcomes and create substantial market value.
Product StageFDA approved/pending approval
/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. ("Inspira," "Inspira Technologies" or the "Company") (Nasdaq: IINN), a pioneering force in the evolution...
growth-positive
Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care
Inspira Technologies OXY B.H.N. Ltd. is advancing its INSPIRA ART500 system, a next-generation device aimed at transforming respiratory care by providing a non-invasive alternative to mechanical ventilation. The company is focusing its financial resources on accelerating the development of this device, which is expected to replace a significant portion of ventilators in the U.S. The INSPIRA ART100, already FDA-cleared, is being deployed in select U.S. centers for clinical evaluation. Additionally, the company plans to submit its HYLA Blood Sensor and Single-Use Patient Kit for FDA approval in the coming years. These developments highlight Inspiras commitment to innovation and its strategic direction towards capturing market demand.
Product StageFDA approved/pending approval
growth-negative
Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
Inspira Technologies OXY B.H.N. Ltd. has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price has been below $1.00 for 30 consecutive days. The company has until September 8, 2025, to regain compliance by maintaining a bid price of at least $1.00 for 10 consecutive days. If compliance is not achieved, a second 180-day period may be granted. Inspira Technologies is developing innovative respiratory support and diagnostic technologies, including the FDA-cleared INSPIRA ART100 system. The company is considering options to address the deficiency and maintain its Nasdaq listing.
/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic...
/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic...
growth-positive
Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates
Inspira Technologies OXY B.H.N. Ltd. announced significant advancements and achievements for the year ending December 31, 2024. The company received FDA 510(k) clearance for its INSPIRA ART100 system and began deploying it in U.S. hospitals. The HYLA blood monitoring sensor, powered by AI, showed promising clinical results and is expected to be submitted for FDA clearance in late 2025. Inspira also established a manufacturing partnership with Zriha Medical Ltd. and reported positive results from a collaboration with Ennocure MedTech Ltd. for infection prevention technology. Additionally, the company strengthened its leadership team with the appointment of a new Chairman and managed costs effectively while focusing on R&D.
Product StagePartnersManagement ChangesFDA approved/pending approval
growth-positive
PESG Report: Inspira Technologies Breaks new Ground with Positive Clinical Data for AI-Powered Blood Sensor Exceeding Expectations
Inspira Technologies has reported groundbreaking clinical results for its AI-powered HYLA blood sensor, achieving 96% accuracy in a key parameter and 92.3% accuracy in detecting oxygen deficiencies. These results validate the companys innovative non-invasive monitoring technology, strengthening its position in the blood gas analyzer and mechanical ventilation markets. The INSPIRA ART100 system, which received FDA 510(k) clearance in May 2024, is being deployed in U.S. hospitals through distribution partner Glo-Med Networks. The company is on track for FDA submission in H2 2025, marking significant progress in its strategy to revolutionize critical care.
Product StageCustomersPartnersFDA approved/pending approval
growth-positive
Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy
Inspira Technologies OXY B.H.N. Ltd. announced positive results from a clinical study of its AI-powered HYLA blood sensor, achieving 96% accuracy in real-time blood monitoring. The study involved 6 patients undergoing open-heart surgery, demonstrating the devices capability to monitor blood without the need for traditional blood draws. Inspira plans to advance with ongoing clinical studies and aims for FDA submission in the second half of 2025. The company targets multiple multi-billion-dollar market segments with this innovative technology, which could transform critical care monitoring by enabling early diagnosis and personalized care.
Product Stage
growth-positive
EXCLUSIVE: Inspira and Ennocure's Bio-Electronic Tech Uses Electric Stimulation to Help Prevent IV-Related Infections
Inspira Technologies OXY B.H.N. announced positive initial results from its collaboration with Ennocure MedTech on a bio-electronic treatment aimed at preventing bloodstream infections related to intravenous lines. The technology, tested on an ex-vivo porcine skin model, showed a 95% reduction in bacterial presence within 4 hours, maintaining effectiveness over 24 hours. This approach uses electric stimulation instead of chemical agents, offering potential advantages in critical care settings, such as extended wear time and real-time monitoring. Despite the promising results, Inspiras stock saw a slight decline in premarket trading.
Product StagePartners
growth-positive
Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections
Inspira Technologies OXY B.H.N. Ltd. announced positive initial results from its collaboration with Ennocure MedTech Ltd. on a novel bio-electronic treatment aimed at preventing bloodstream infections. The ex-vivo testing demonstrated a 95% reduction in bacterial presence within 4 hours using a bio-electronic patch, which uses physical electric stimulation. This innovative approach could offer significant advantages in critical care settings by preventing bacterial growth and reducing the frequency of dressing changes. Inspiras pipeline products, including the INSPIRA™ ART and HYLA™ blood sensor, are in development and have not yet received regulatory approval. The company has received FDA clearance for its INSPIRA™ ART100 system for specific procedures.
Product StagePartnersFDA approved/pending approval
growth-positive
/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today...
Inspira Technologies OXY B.H.N. Ltd. has announced positive initial results from its collaboration with Ennocure MedTech Ltd. to develop a bio-electronic treatment for preventing bloodstream infections. The ex-vivo testing demonstrated a 95% reduction in bacterial presence within 4 hours, showcasing the potential of this technology in critical care settings. The innovative approach uses physical electric stimulation rather than chemical agents, offering advantages such as extended wear time and real-time monitoring capabilities. Inspiras pipeline products, including the INSPIRA™ ART and HYLA™ blood sensor, are in development stages. The company is also working on AI-driven personalized therapy for remote wound monitoring. The collaboration with Ennocure highlights Inspiras commitment to advancing infection prevention technology.
Product StagePartners
growth-negative
Inspira Technologies Oxy B.H.N. Ltd. (IINN) Enhances HYLA™ Sensor with AI Oxygenation Indicator
DeepSeek, a Chinese AI startup, faces significant challenges as multiple countries, including South Korea, Australia, and the United States, have banned its AI services due to security concerns. These bans affect government systems and devices, with entities like the US Navy and Korea Hydro & Nuclear Power restricting the use of DeepSeeks AI. The bans are not due to the companys Chinese origin but rather the perceived security risks associated with its AI technology. This situation highlights the growing scrutiny and caution surrounding AI technologies, particularly those with potential security vulnerabilities.
growth-positive
PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon
Inspira Technologies has announced a significant advancement in its AI-driven medical platform with the integration of a next-generation oxygenation indicator into its HYLA blood sensor technology. This enhancement allows for rapid detection of critical oxygen-related conditions without requiring intermittent blood draws, representing a potential breakthrough in continuous patient monitoring. The HYLA system, currently undergoing clinical evaluation at Sheba Medical Center, leverages AI to provide real-time monitoring of vital blood parameters. The company plans for 510(k) FDA submissions in the second half of 2025. This development strengthens Inspiras position in the $2.5 billion blood gas analysis market and the $19 billion mechanical ventilation market.
Product StageFDA approved/pending approval
growth-positive
/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today...
Inspira Technologies has announced the integration of a next-generation oxygenation indicator into its AI-powered HYLA blood sensor technology. This advancement is designed to enhance critical care monitoring by enabling continuous, real-time monitoring of tissue oxygenation and early detection of hypoxia. The technology is currently undergoing clinical validation at Sheba Medical Center, with preliminary results expected soon. Inspira plans to submit for FDA regulatory clearance in the second half of 2025. The HYLA sensor, combined with the FDA-cleared INSPIRA ART100 system, aims to revolutionize patient care by providing non-invasive, continuous monitoring. This development positions Inspira as a significant player in the point-of-care testing and arterial blood gas analyzer market.
Product StageFDA approved/pending approval
growth-positive
EXCLUSIVE: Isreal-Based Inspira Technologies Integrates New Oxygenation Indicator Into HYLA Blood Sensor To Enhance Critical Care Monitoring
Inspira Technologies OXY B.H.N. Ltd. has announced the integration of a new oxygenation indicator into its AI-powered HYLA blood sensor technology. This advancement aims to enhance critical care monitoring by enabling rapid detection of oxygen-related conditions without intermittent blood draws. The technology provides real-time, continuous monitoring of oxygenation therapy and is undergoing clinical validation at Sheba Medical Center. An FDA submission for regulatory clearance is anticipated in the second half of 2025. This integration strengthens HYLAs position in the point-of-care testing market and complements the FDA-cleared INSPIRA ART100 system, which targets the mechanical ventilation market.
Product Stage
growth-positive
Inspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor
Inspira Technologies OXY B.H.N. Ltd. has announced the integration of an advanced oxygenation indicator into its AI-powered HYLA blood sensor technology. This development aims to enhance critical care monitoring by enabling real-time, continuous monitoring of tissue oxygenation and early detection of hypoxia. The technology is currently undergoing clinical validation at Sheba Medical Center, with preliminary results expected soon. The company anticipates submitting for FDA regulatory clearance in the second half of 2025. This advancement positions HYLA as a potential leader in the point-of-care testing and arterial blood gas analyzer market.
Product StageFDA approved/pending approval
growth-positive
Inspira™ Introduces Advanced Features for INSPIRA™ ART100, Further Amplifying User and System Support
Inspira Technologies OXY B.H.N. Ltd. has announced new support features for its INSPIRA ART100 system, which has been cleared by the FDA. These enhancements aim to improve efficiency and reduce staff overhead in medical procedures, reinforcing Inspiras leadership in extracorporeal life support technology. The system integrates with hospital procedures, includes alarm troubleshooting, and features an advanced display for critical care situations. The INSPIRA ART100 is designed to oxygenate blood and remove carbon dioxide, potentially replacing mechanical ventilators in the $19 billion market. It also includes the HYLA blood sensor for real-time monitoring. Inspira is committed to pioneering life support innovations.
Product Stage
growth-positive
Inspira™ Technologies Prepares its First Life-Support Systems for Deployment at a Leading U.S. Hospital
Inspira Technologies Oxy B.H.N. Ltd. has announced the delivery of its INSPIRA™ ART100 systems to Glo-Med Networks Inc., marking a significant step in deploying its groundbreaking respiratory support technology in the U.S. market. The systems are set for deployment at a leading U.S. hospital, with support from both Inspira and Glo-Med teams to ensure seamless integration. The INSPIRA™ ART100, designed in collaboration with U.S. clinicians, aims to revolutionize extracorporeal blood circulation. Additionally, the HYLA™ blood monitoring technology is undergoing clinical evaluations, with plans for FDA submission in 2025. This development aligns with Inspiras goal to introduce its technologies to U.S. physicians and perfusionists, potentially replacing traditional mechanical ventilators.
Product StageCustomersPartners
growth-positive
/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking...
Inspira Technologies Oxy B.H.N. Ltd. has announced the delivery of its INSPIRA™ ART100 systems to Glo-Med Networks Inc., marking a significant step in its deployment at a leading U.S. hospital. This deployment aims to introduce the companys groundbreaking respiratory support technology to the U.S. market. The INSPIRA™ ART100 system, which has received FDA 510(k) clearance, is designed to revolutionize extracorporeal blood circulation and is expected to be integrated with the HYLA™ blood monitoring technology. The company plans to submit the HYLA™ for FDA approval in 2025. This strategic move is expected to enhance Inspiras brand presence among U.S. physicians and perfusionists.
Product StageFDA approved/pending approval
growth-positive
Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors
Inspira Technologies OXY B.H.N. Ltd. has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025. Mr. Parnes brings over three decades of experience in the technology sector, particularly in medical technology and pharmaceuticals. His leadership is expected to enhance the companys strategic vision and competitive advantage. The company expressed gratitude to Prof. Benad Goldwasser for his contributions as the previous chairman, who resigned due to personal reasons. This leadership change is seen as a positive step towards sustainable growth and innovation for Inspira Technologies.
Management Changes
growth-positive
/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology...
Inspira Technologies OXY B.H.N. Ltd., a leader in life-support technology innovation, has appointed Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025. Mr. Parnes brings extensive experience in the medical technology and pharmaceutical industries, having served in various leadership roles. His appointment is expected to enhance the companys strategic vision and competitive advantage. Inspira Technologies has developed the INSPIRA™ ART, a breakthrough device for respiratory treatment, which has received FDA 510(k) clearance for certain procedures. The company is also developing other products like the INSPIRA ART500, Cardi-ART, VORTX Oxygen Delivery System, and HYLA blood sensor, which are still in the design and development phase.
Management Changes
growth-positive
Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line
Inspira Technologies OXY B.H.N. Ltd., a leader in life-support technology innovation, has announced a collaboration with Zriha Medical Ltd to establish a dedicated production line for a crucial component of its respiratory support system. This partnership aims to scale up production of Inspiras innovative technologies, potentially accelerating their market entry. Zriha Medical, with over 50 years of experience in medical device manufacturing, will leverage its state-of-the-art clean room facilities and ISO 13485 certification to produce critical components for Inspiras devices. The collaboration is expected to enhance Inspiras strategy and support its groundbreaking Augmented Respiration Technology (INSPIRA™ ART), which offers an alternative to mechanical ventilators.
Partners
growth-positive
Inspira™ Technologies Unveils Modular Configuration for Revolutionary VORTX™ Blood Oxygenation Delivery Technology
Inspira Technologies OXY B.H.N. Ltd. has announced the development of a modular configuration for its VORTX blood oxygenation delivery technology. This advancement is expected to significantly impact the field of extracorporeal oxygenation and transform critical care practices globally. The VORTX system, part of Inspiras INSPIRA ART, is designed to revolutionize the $19 billion mechanical ventilation market by providing an alternative to traditional ventilators. The technology is protected by 32 novel patent claims and aims to maintain natural blood flow, potentially reducing harmful effects on blood components. Inspiras commitment to advancing respiratory care is evident in its continuous development of innovative solutions to improve patient outcomes.
growth-positive
/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, is...
Inspira Technologies OXY B.H.N. Ltd. has announced the development of a modular configuration for its VORTX blood oxygenation delivery technology, which aims to revolutionize the $19 billion mechanical ventilation market. The VORTX system is designed to maintain natural blood flow, potentially reducing harmful effects on blood components. The companys flagship product, INSPIRA ART, offers an alternative to mechanical ventilators by stabilizing oxygen levels without a ventilator. The company has received FDA 510(k) clearance for its INSPIRA ART100 system for use in CBP procedures. Other products, including the INSPIRA ART500 and VORTX, are still in development. The technology is protected by 32 patent claims and aims to improve patient outcomes in critical care.
Product StageFDA approved/pending approval
growth-positive
EXCLUSIVE: Inspira Technologies Unveils Modular Configuration For VORTX Blood Oxygenation Delivery Technology
Inspira Technologies announced a modular configuration for its VORTX blood oxygenation delivery technology, which aims to enhance the companys Augmented Respiration Technology (ART) system. The VORTX technology is designed to oxygenate blood without using fiber membranes, potentially reducing damage to blood cells. This innovation could revolutionize the $19 billion mechanical ventilation market by providing a more natural blood flow and reducing harmful effects. Inspira recently secured a U.S. patent for the VORTX system and is preparing for a production ramp-up of its ART100 device due to a recent hMPV outbreak in China. The companys stock was down 1.89% at $1.04 during the premarket session.
Expand
growth-positive
Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China
Inspira Technologies OXY B.H.N. Ltd., a leader in life-support technology, is preparing for a potential production ramp-up of its INSPIRA™ ART100 device in response to the recent outbreak of human metapneumovirus (hMPV) in China. The company is in discussions with providers in affected regions to evaluate demand and ensure rapid response capabilities. Inspira is working with suppliers to secure necessary materials and is ready to adjust production plans as needed. The INSPIRA ART100 device offers a breakthrough in respiratory care by stabilizing oxygen saturation levels without a ventilator. The company emphasizes its preparedness as a precautionary measure aligned with its commitment to global health readiness.
Product Stage
growth-positive
/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking...
Inspira Technologies Oxy B.H.N. Ltd. is set to showcase its FDA-cleared INSPIRA ART100 system at the Arab Health 2025 conference in Dubai. The INSPIRA ART100 is a cardiopulmonary bypass system that aids in respiratory care by oxygenating blood and removing carbon dioxide, effectively supporting heart and lung functions in critical care patients. The system is equipped with proprietary software and advanced features for improved patient care. The event presents an opportunity for Inspira to explore new markets and form partnerships to expand the adoption of its innovative respiratory solutions. The company aims to disrupt the $19 billion mechanical ventilation market with its technology.
Product StageFDA approved/pending approvalPartners
growth-positive
Inspira™ Technologies Flagship Technology to be Showcased at Arab Health Expo 2025 in Dubai
Inspira Technologies Oxy B.H.N. Ltd., a company specializing in respiratory support technology, will showcase its FDA-cleared INSPIRA™ ART100 system at the Arab Health 2025 exhibition in Dubai. The INSPIRA ART100 is a cardiopulmonary bypass system designed to enhance respiratory care by adding oxygen to the blood and removing carbon dioxide. It features proprietary software for setup assistance and advanced customization options for patient care. The system is compact, offers up to four hours of emergency uptime, and is compatible with various disposables. The Arab Health Expo provides a platform for Inspira to present its innovative technologies to global healthcare leaders and explore new market opportunities and partnerships.
FDA approvedPartners
growth-positive
Inspira™ Announces Pricing of $3.2M Private Placement by New and Existing Investors of the Company
Inspira Technologies Oxy B.H.N. Ltd., a leader in respiratory support technology, announced a private placement offering of 4,608,715 ordinary shares and warrants at a combined price of $0.70 per share. The warrants have an 18-month term and an exercise price of $1.10 per share. The company plans to use the proceeds for working capital and general corporate purposes. The closing is expected around December 30, 2024, with Dawson James Securities as the exclusive placement agent. Inspiras innovative INSPIRA ART device aims to revolutionize the mechanical ventilation market by offering a non-invasive alternative for patients with acute respiratory failure.
Investment
growth-positive
Inspira™ Technologies Delivers Systems to Leading Distributor for U.S. Deployment
Inspira Technologies Oxy B.H.N. Ltd. has delivered its INSPIRA™ ART100 systems to its U.S. distributor, Glo-Med Networks Inc. The systems will be distributed to hospitals on the U.S. east coast, including a top-ranked cardiothoracic surgery division in New York. This marks a significant step in introducing Inspiras technology to the U.S. market. The INSPIRA™ ART100, designed with U.S. clinicians, optimizes patient care during critical times and is set to integrate with the HYLA™ blood monitoring technology. The HYLA™ is undergoing clinical evaluations at Sheba Hospital and is planned for FDA submission in 2025. This deployment is part of Inspiras strategy to revolutionize acute respiratory care and tap into the $19 billion mechanical ventilation market.
CustomersPartners
growth-positive
/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory...
Inspira Technologies Oxy B.H.N. Ltd. has announced the delivery of its INSPIRA™ ART100 systems to its U.S. distributor, Glo-Med Networks Inc. The systems will be distributed to hospitals on the U.S. east coast, including a top-ranked cardiothoracic surgery division in New York. This move aims to introduce Inspiras technologies to physicians and perfusionists. The INSPIRA™ ART100 system, designed with U.S. clinicians, optimizes extracorporeal blood circulation and is planned to be integrated with the HYLA™ blood monitoring technology. The HYLA™ is undergoing clinical evaluations at Sheba Hospital in preparation for an FDA submission in 2025. The company sees this as a step towards revolutionizing acute respiratory care. Inspira Technologies is a leader in life support and respiratory treatment, with its products aiming to offer alternatives to traditional mechanical ventilation.
CustomersPartners
growth-positive
Inspira™ Expands HYLA™ Blood Sensor Technology into Personalized Blood Lab Testing for Rapid Detection of Serious Medical Conditions
Inspira Technologies Oxy B.H.N. Ltd. has announced the expansion of its HYLA blood sensor technology into a personalized Blood Lab Test. This innovation aims to perform real-time patient blood work, potentially replacing the need for physical blood samples and reducing the burden on hospital staff. The HYLA technology is undergoing clinical evaluations at Sheba Hospital, with plans for a U.S. FDA submission in 2025. The companys broader strategy includes the INSPIRA ART device, which offers an alternative to mechanical ventilators by stabilizing oxygen levels without the need for sedation. This development is part of Inspiras efforts to revolutionize the $19 billion mechanical ventilation market.
Expand
growth-positive
/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies" or the "Company"), a groundbreaking life support technology...
Inspira Technologies Oxy B.H.N. Ltd., a life support technology company, has announced the expansion of its HYLA blood sensor technology into a personalized Blood Lab Test. This innovation aims to perform real-time blood work, potentially replacing the need for physical blood samples and reducing reliance on central labs. The HYLA technology is undergoing clinical evaluations at Sheba Hospital and is part of a broader strategy to revolutionize patient care in ERs, ICUs, and operating rooms. The company plans to submit the first configuration of HYLA for FDA approval in 2025. Inspiras INSPIRA ART technology, which has already received FDA clearance for certain procedures, aims to disrupt the $19 billion mechanical ventilation market by offering an alternative to traditional ventilators.
growth-positive
Inspira™ Collaborates with New York's Westchester Medical Center to Evaluate the INSPIRA™ ART100 Functionality and Performance in Clinical Scenarios
Inspira Technologies OXY B.H.N. Ltd. has entered into a strategic collaboration with Westchester Medical Center in Valhalla, New York. This partnership aims to evaluate the performance of Inspiras FDA-cleared INSPIRA ART100 systems in real-world clinical scenarios. The collaboration is intended to advance critical patient care by deploying Inspiras proprietary technology, which is designed to treat acute respiratory failure without mechanical ventilators. The partnership highlights Westchester Medical Centers commitment to integrating innovative technologies to improve patient outcomes. This collaboration is seen as a validation of the growing interest in Inspiras technology and provides an opportunity to demonstrate its capabilities within a premier medical network.
Partners
growth-positive
/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN), (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking...
Inspira Technologies OXY B.H.N. Ltd. has entered into a strategic collaboration with Westchester Medical Center in Valhalla, New York. This partnership aims to evaluate the performance of Inspiras FDA-cleared INSPIRA ART100 systems in real-world clinical scenarios. The collaboration is expected to advance critical patient care and explore long-term deployment of Inspiras next-generation technology, the INSPIRA ART system, designed to treat acute respiratory failure. The partnership highlights Westchester Medical Centers commitment to innovative technologies and positions it to enhance treatment outcomes. This collaboration is seen as a validation of the growing interest in Inspiras technology, offering an opportunity to demonstrate its capabilities in a premier medical network.
Partners
growth-positive
Join Inspira™ Technologies' Live Investor Webinar and Q&A Session on November 11
Inspira Technologies Oxy B.H.N. Ltd., a medical technology company, is hosting a webinar on November 11, 2024, to discuss its innovative developments in life support technology. The company has developed the INSPIRA™ ART, a device designed to elevate and stabilize blood oxygen levels without mechanical ventilation, potentially disrupting the $19 billion mechanical ventilation market. The webinar, hosted by RedChip Companies, will feature a presentation by Joe Hayon, President of Inspira Technologies, followed by a live Q&A session. The INSPIRA ART is equipped with the HYLA™ blood sensor for real-time monitoring, aiming to assist physicians in making informed decisions. The event highlights the companys growth potential and innovative approach in the respiratory treatment arena.
growth-positive
/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), ("Inspira Technologies" or the "Company"), an innovative medical technology company in the...
Inspira Technologies Oxy B.H.N. Ltd., a medical technology company, is hosting a webinar on November 11, 2024, to discuss its innovative developments in life support technology. The company has developed the INSPIRA™ ART, a device designed to stabilize blood oxygen levels without mechanical ventilation, potentially disrupting the $19 billion mechanical ventilation market. The webinar, hosted by RedChip Companies, will feature a presentation by Joe Hayon, President of Inspira Technologies, followed by a live Q&A session. The INSPIRA ART is equipped with the HYLA™ blood sensor, which provides real-time blood monitoring, aiding physicians in patient care. This innovation could significantly impact the treatment of patients with acute respiratory failure.
growth-positive
/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support...
Inspira Technologies OXY B.H.N. Ltd. has signed a distribution agreement with Glo-Med Networks Inc, making Glo-Med the primary distributor and customer support center for Inspiras products in the U.S. The agreement aims to enhance operational efficiency and customer service capabilities in the U.S. market, particularly for the INSPIRA ART100 system, which has FDA clearance for Cardiopulmonary Bypass procedures. The distribution facility in Florida will support the deployment and maintenance of the system and potentially facilitate the commercialization of additional products. The partnership with Med-Stat Consulting Services will provide certified after-market services. This agreement is seen as a crucial milestone for Inspiras market introduction and future product launches.
Partners
growth-positive
Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100
Inspira Technologies OXY B.H.N. Ltd. has signed a distribution agreement with Glo-Med Networks Inc, appointing them as the primary distributor and customer support center for the INSPIRA ART100 in the U.S. This agreement aims to enhance Inspiras operational efficiency and customer service capabilities, targeting a $19 billion market opportunity. The distribution facility in Florida will support the deployment and maintenance of the INSPIRA ART100 system and facilitate the commercialization of additional products. The facility will also provide comprehensive support services through a partnership with Med-Stat Consulting Services. This strategic move is expected to introduce Inspiras technologies to U.S. healthcare providers, preparing for the future deployment of the flagship INSPIRA ART.
PartnersCustomers
growth-positive
Inspira™ Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism
Inspira Technologies OXY B.H.N. Ltd. announced the development of a new disposable kit aimed at the perfusion market, which is part of their strategy to generate recurring revenues. The kit is designed to be compatible with the INSPIRA ART100 system and other life support machines, potentially tapping into a $1 billion market. The disposable kit will undergo FDA clearance, and once approved, it will be marketed to hospitals using the INSPIRA ART100 system. The INSPIRA ART100 has already received FDA and Israeli certifications for specific medical procedures. This innovation is expected to enhance product safety and improve patient care, marking a positive growth step for the company.
Customers
growth-positive
Inspira Stock to Gain From its Appearance at Annual ELSO Conference
Inspira Technologies OXY B.H.N. Ltd. (IINN) recently announced its participation in the 34th Annual Extracorporeal Life Support Organization (ELSO) conference in Detroit, MI, scheduled for September 29-30, 2024. The company will showcase its latest technologies, including the INSPIRA ART100 system, which has received FDA clearance for cardiopulmonary bypass procedures. Following the announcement, IINNs stock rose by 0.8% to $1.22. The company is expected to benefit from its expanding INSPIRA ART pipeline and has a market capitalization of $22.6 million. Inspiras U.S. sales team, along with key executives, will be present at the conference. The company also secured a new U.S. patent for its VORTX orbiting blood oxygenation delivery system and listed its INSPIRA CART with the FDA in recent months.
CustomersPartners
growth-positive
Inspira™ Launches INSPIRA™ ART100 at the World's Largest Extracorporeal Life Support Conference
Inspira Technologies OXY B.H.N. Ltd. will present its latest extracorporeal blood circulation technologies at the 34th Annual ELSO Conference in Detroit, Michigan, on September 29-30, 2024. The company will showcase the FDA-cleared INSPIRA™ ART100 system, which will be deployed in the U.S. market. The U.S. sales team, led by Glo-Med Networks Inc., will support the rollout. The event will feature interactive demonstrations and presentations, highlighting the systems key design features and advantages. Inspira aims to provide innovative solutions in respiratory treatment, potentially reducing the need for invasive mechanical ventilation.
CustomersPartners
growth-positive
IINN Stock Gains on Second US Patent Approval for VORTX System
Inspira Technologies OXY B.H.N. Ltd. (IINN) has secured an additional U.S. Patent approval for its VORTX orbiting blood oxygenation delivery system, a core technology of the INSPIRA ART device. This development marks a significant milestone for the company, advancing its blood oxygenation technologies. Following the announcement, IINN shares rose by 5.2% to $1.21. The INSPIRA ART device aims to offer a safer alternative to traditional mechanical ventilators, potentially impacting the $19 billion mechanical ventilation market. The company has also received FDA 510(k) clearance and Israeli AMAR certification for its INSPIRA ART100 system. The global oxygen delivery system market is expected to grow, driven by the prevalence of respiratory diseases and improved healthcare infrastructure.
Investment
growth-positive
Inspira gains new US patent approval for blood oxygenation system
Inspira Technologies has secured a second US patent approval for its VORTX orbiting blood oxygenation delivery system, a key component of the INSPIRA ART device. This system is designed to oxygenate blood without using fibre membranes, potentially revolutionizing the medical field by reducing blood damage and associated costs. The approval brings the total number of new claims for the technology to 32. The INSPIRA ART device aims to support patients in intensive care units with respiratory failure, reducing the need for mechanical ventilators. The company has also received various certifications and approvals, including from the Israeli Ministry of Health and the US FDA.
Investment
growth-positive
Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System
Inspira Technologies has secured an additional U.S. Patent approval for its VORTX™ orbiting blood oxygenation delivery system, a core technology of the INSPIRA™ ART device. This technology aims to revolutionize the $19 billion mechanical ventilation market by providing an alternative to mechanical ventilators for the 20 million ICU patients with respiratory failure annually. The INSPIRA™ ART device is designed to maintain stable oxygen saturation levels without the need for ventilators, allowing patients to remain awake during treatment. The company has also obtained FDA 510(k) clearance for its INSPIRA™ ART100 system for use in Cardiopulmonary Bypass procedures.
growth-positive
Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock
Inspira Technologies OXY B.H.N. Ltd. announced plans to report clinical results for its HYLA blood sensor in open-heart surgery patients. The HYLA sensor is designed to monitor vital blood parameters in real-time, potentially preventing complications and enhancing patient outcomes. The clinical study results are expected in Q4 2024, with a 510(k) submission to the FDA in early 2025. Inspira aims to integrate the HYLA sensor with its FDA-cleared INSPIRA ART100 system. The company is expanding its product line and targeting a $59 billion market opportunity. Recent developments include FDA listing for its INSPIRA CART and positive evaluation results for its INSPIRA ART100 system. Shares of Inspira have increased by 1.9% this year.
Expand
growth-positive
/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology...
Inspira Technologies OXY B.H.N. Ltd. announced plans to report clinical results for its new HYLA™ blood sensor, designed for real-time, continuous monitoring of blood parameters. Targeting a $2.5 billion market, the sensor aims to alert physicians of changes in a patients condition without the need for intermittent blood samples. The company plans to expand its blood testing facilities and aims for a 510(k) submission to the FDA in early 2025. The HYLA™ sensor will integrate with the FDA-cleared INSPIRA™ ART100 systems. Inspira is also developing other products like the INSPIRA™ Cardi-ART and INSPIRA™ ART (Gen 2).
Expand
growth-positive
Inspira™ to Publish HYLA™ Clinical Results in Fourth Quarter 2024
Inspira Technologies OXY B.H.N. Ltd. announced plans to report clinical results for its new HYLA™ blood sensor, which aims to provide real-time, continuous monitoring of blood parameters without the need for intermittent blood samples. This technology targets a $2.5 billion market and is expected to be a key milestone for the companys growth. The clinical study results are anticipated in Q4 2024, with a 510(k) submission to the FDA planned for early 2025. The company is expanding its blood testing facilities to accelerate the development of HYLA™ and aims to deploy its FDA-cleared INSPIRA™ ART100 system in top hospitals in the U.S. and Israel.
CustomersExpand
growth-positive
INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare
Inspira Technologies recently announced the FDA listing of its INSPIRA CART, a medical cart designed for use with the INSPIRA ART100 system, aimed at enhancing healthcare delivery in operating rooms during cardiopulmonary bypass procedures. The FDA classification as a Class I Medical Device and 510(K) Exempt highlights its compliance with rigorous safety and efficacy standards, paving the way for its introduction to the U.S. market. The company has received its first order from Glo-Med Networks, Inc. Inspira is also advancing its product pipeline, which includes the HYLA blood sensor, the INSPIRA Cardi-ART, and the INSPIRA ART (Gen 2), or ART500.
CustomersPartnersExpand
Growth-Positive
Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product
Inspira Technologies, a leader in life-support technology innovation, has announced the FDA listing of its medical cart, INSPIRA™ CART, designed for use with the INSPIRA™ ART100 system. The cart is intended for use by medical professionals in operating rooms in the United States during Cardiopulmonary Bypass procedures. The company has already received its first order of INSPIRA™ CARTs from Glo-Med Networks, Inc. Inspira is also working to deploy the FDA cleared INSPIRA™ ART100 system in leading U.S and Israeli hospitals and continues to develop its INSPIRA™ ART pipeline.
CustomersPartnersExpand
growth-positive
Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 - Results Exceed 100% at Maximum Flow
Inspira Technologies, a company specializing in life-support technology, has announced successful evaluation results for its proprietary INSPIRA ART100 system. The evaluation was conducted by Inspira researchers and involved testing the systems compatibility and performance with key products of a leading medical technology company. The tests exceeded 100% of the standard value for gas transfer at maximum flow. The successful results indicate the systems power and versatility and its potential for meaningful business development activities. The INSPIRA ART100 system is designed to provide a comprehensive platform of efficiency, compatibility, and performance, enabling medical technologies companies to refine and optimize their products for improved patient care.
growth-positive
Inspira™ Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest
Inspira Technologies has introduced the INSPIRA Cardi-ART, a portable modular device designed to provide oxygen to the brain during cardiac arrest. The device, which is currently in development, is expected to expand the INSPIRA ART platform to a wider range of applications with a combined potential market of approximately $58.8 billion. The INSPIRA Cardi-ART is being designed to support vital organ oxygenation during cardiac arrest to treat patients both in and outside of hospitals. The company plans to submit the device to the U.S. Food and Drug Administration for approval as early as 2026.
InvestmentExpand
growth-positive
Inspira Technologies gains key Israeli approval for INSPIRA ART100 system
Inspira Technologies OXY has received approval from the Israeli Ministry of Health for its INSPIRA ART100 system, a significant step in the companys efforts to commercialise its medical technology. The approval is for the systems use in extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures. This regulatory approval is crucial for Inspira Technologies, as it supports the companys strategy to initiate business development activities to introduce its innovative products to the market. The company has previously secured the US Food and Drug Administration (FDA) 510(k) clearance for the INSPIRA ART100 system for cardiopulmonary bypass procedures.
CustomersPartners
growth-positive
Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System
Inspira Technologies OXY B.H.N. Ltd., a medical technology company, has received approval from the Israeli Ministry of Health for its INSPIRA ART100, an Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass system. This follows the FDA clearance announced on May 28, 2024. The company believes that this approval is an important step towards growing local support and adoption for the INSPIRA ART100 and demonstrates Inspiras capabilities in obtaining regulatory approvals for its products. The approval will also facilitate the creation of business opportunities in new regions and emerging markets.
CustomersExpand
growth-positive
Inspira (IINN) Unveils Business Targets for 2024-25
Inspira Technologies OXY B.H.N. Ltd. has disclosed a new business plan focusing on next-generation technologies. The company is planning to strengthen its position in the mechanical ventilation market with its flagship INSPIRA ART (Gen 2) device and deploy INSPIRA ART100, its cardiopulmonary support device, in the United States and abroad. The company has received the first purchase order from the U.S. distributor, Glo-Med Networks, Inc. and plans to distribute its 501(k) FDA-cleared INSPIRA ART100 system in multiple sites and countries. Inspira is also planning to submit its HYLA blood sensor for FDA Clearance and integrate the technology into the next generation of the INSPIRA ART100 device.
CustomersPartnersExpand
growth-positive
Inspira™ Announces Business Plan Targets
Inspira™ Technologies OXY B.H.N. Ltd., a medical technology company, has announced plans to aggressively promote its INSPIRA™ ART100 device in the U.S. and other markets following FDA clearance. The company is also accelerating plans for its next-generation INSPIRA™ ART (Gen2) device, which aims to eliminate the need for traditional mechanical ventilators. The company is targeting a share of the $19 billion mechanical ventilation market. Under existing distribution agreements with Glo-Med Networks, Inc, Inspira has received its first purchase order from the U.S. distributor, with the first shipment scheduled for Q4 2024.
CustomersPartnersExpand
growth-positive
Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel
Inspira Technologies, a medical technology company, will present at the annual iECMO Conference in Herzliya, Israel on June 18th, 2024. The company will present the INSPIRA ART100 System, which has recently received clearance from the U.S. Food and Drug Administration and is pending approval from AMAR, the medical device division of the Israeli Ministry of Health. The companys research and development team will be available at the conference to answer questions about its technologies and products currently in development.
CustomersExpand
growth-positive
Inspira™ Receives First Ever Purchase Order for INSPIRA™ ART100 Systems in the U.S.
Inspira™ Technologies OXY B.H.N. Ltd. has received its first purchase order from Glo-Med Networks, Inc. for its INSPIRA™ ART100 systems, with the first five units expected to be shipped in Q4 2024. The order also includes the potential purchase of an additional 20 systems. The INSPIRA™ ART100 is a breakthrough medical technology designed to replace the need for mechanical ventilation. The company plans to offer hospitals receiving the INSPIRA™ ART100 an option with special terms for the integrated HYLA™ Blood Sensor and INSPIRA™ ART (Gen 2) devices.
CustomersPartnersExpand
Growth-Positive
Inspira™ to Exhibit the FDA Cleared INSPIRA™ ART100 System at a World-Renowned Event in the Sector
Inspira Technologies OXY B.H.N. Ltd., a medical technology company, has announced plans to exhibit its INSPIRA ART100 System at the Extracorporeal Life Support Organization (ELSO) conference in Detroit, Michigan from September 29 to October 1, 2024. The system, which has been cleared by the U.S. Food and Drug Administration (FDA), will be presented to healthcare representatives, physicians, perfusionists, and medical device companies. The INSPIRA ART100 system is designed for use by licensed physicians and perfusionists to perform cardiopulmonary bypass procedures.
CustomersPartners
growth-positive
Inspira™ Technologies Announces Business Targets Presentation Following FDA Clearance and Significant Developments
Inspira™ Technologies OXY B.H.N. Ltd., a medical technology company, has announced a conference call to be held on June 20, 2024, where Company President, Director, and co-founder, Mr. Joe Hayon, will discuss the companys business targets, distribution agreements, and future steps. This follows the FDA clearance for the INSPIRA™ ART100 system, a significant milestone for the company. The INSPIRA™ ART100 is a Cardiopulmonary Bypass System designed to measure the patients blood parameters in real-time, potentially allowing patients to remain awake during treatment.
Management ChangesPartners
growth-positive
Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant
Inspira Technologies has received FDA 510(k) clearance for its INSPIRA ART100, a Cardiopulmonary Bypass System. The device is used in an extracorporeal perfusion circuit to pump blood during brief cardiac bypass procedures. The INSPIRA ART100 will work with Inspiras AI-powered Clip-On HYLA blood sensor and tube, enabling real-time blood parameter measurements. The company aims to revolutionize external mechanical ventilation machinery for the nearly 20 million people who need ventilation and oxygenation annually. The global cardiopulmonary bypass equipment market size was in $421 million 2021 and is expected to reach $810.9 million by 2028.
InvestmentPartners
Growth-Positive
INSPIRA™ ART100 Receives FDA 510(k) Clearance
Inspira Technologies, a medical technology company, has received 510(k) class II clearance from the U.S. Food and Drug Administration (FDA) for its INSPIRA ART100, a Cardiopulmonary Bypass System. The system is designed to continuously measure the patients blood parameters in real-time, delivering needed oxygen volume straight into the blood. This technology potentially allows patients to remain awake during treatment and may enable patients to be treated in and beyond intensive care units, reducing the need for mechanical ventilation systems.
InvestmentPartners
growth-positive
Inspira™ Announces Start of Production of the INSPIRA™ ART100
Inspira Technologies, a medical technology company, has announced the start of production for its INSPIRA ART100 medical device. The device is being manufactured by a leading technology company that provides electronic assembly solutions for various industries. The first batch of devices will be used for deployment in several initial sites, subject to U.S. Food and Drug Administration (FDA) regulatory clearance. The INSPIRA ART100 is designed to rebalance patient oxygen saturation levels, potentially allowing patients to remain awake during treatment while reducing the need for invasive, risky, and costly mechanical ventilation systems.
CustomersPartners
Growth-Positive
Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100
Inspira Technologies OXY B.H.N. Ltd., a medical technology company, has received the Canadian Standards Association (CSA) Certification of Compliance to U.S. standards for its INSPIRA ART100 device. The certification is an important milestone towards gaining market access for the medical device, pending U.S. Food and Drug Administration (FDA) regulatory clearance. The CSA mark signifies the products compliance with safety and performance requirements. The INSPIRA ART100 is designed to rebalance patient oxygen saturation levels, potentially reducing the need for invasive mechanical ventilation systems.
Customers
growth-positive
Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures
Inspira Technologies has signed a collaboration term sheet with Beilinson Hospital in Israel to evaluate its INSPIRA ART100 device in organ transplant procedures. The hospital will provide Inspira with access to data and diagnostics from the use of the device and user feedback. Beilinson Hospital is the leading organ transplant center in Israel, conducting over 70% of the organ transplants in the country. The collaboration agreement is conditional on regulatory clearance for the device from the Israeli Ministry of Health Medical Device Division.
Partners
Growth-Positive
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
Inspira Technologies, a medical technology company, and Ennocure MedTech Ltd. have announced results from their collaborative development of a proprietary bio-electronic treatment to prevent bloodstream infections in intensive care unit patients. The in vitro study showed a 75% reduction in bacterial growth 4 hours after the application of the treatment and a 100% reduction within 24 hours. The technology uses electrical pulses to inhibit bacterial proliferation. Inspira plans to integrate this technology into the INSPIRA ART patient treatment. The next step involves conducting tests on an ex vivo model in anticipation of the first prospective first-in-human trials.
PartnersResearch and Development
growth-positive
Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb
Inspira Technologies has announced the start of a program to explore the use of its INSPIRA ART100 device as an artificial womb for neonates in need of respiratory support. The device could potentially replace mechanical ventilators, which can have long-term negative effects on neonates. The additional application of the device is aimed at prematurely born neonates with underdeveloped respiratory systems and neonates with life-threatening disorders. The companys products have not yet been tested or used in humans and have not been approved by any regulatory entity.
CustomersExpand
growth-positive
Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager
Inspira Technologies has announced a strategic investment by Ronen Juster and Margi Ben-Noon, the mother of Inspiras CEO. The company will issue and sell 1,339,285 ordinary shares at a price per share of $1.232, in a registered direct offering. The offering is expected to close on April 2, 2024, and the proceeds, expected to be $1.65 million, will be used for working capital and general corporate purposes.
Investment
growth-negative
Companies Like Inspira Technologies Oxy B.H.N (NASDAQ:IINN) Could Be Quite Risky
Inspira Technologies Oxy B.H.N is facing a cash burn situation, with its cash burn increasing by 30% over the last year. As of December 2023, the company had a cash runway of approximately 9 months, indicating the need to either reduce its annual cash burn or replenish its cash. The companys cash burn of $10.0m is about 40% of its $25m market capitalisation, which could lead to a painful capital raising. The article suggests that the companys cash burn situation is fairly risky.
Investment
growth-positive
Inspira™ Technologies Reports Full Year 2023 Financial Results
Inspira Technologies OXY B.H.N. Ltd. has announced its financial results for the year ended December 31, 2023. The company has made significant progress in diversifying its business development and has reached important milestones that are expected to drive its next generation innovations and market launch of its products. The company has submitted its blood oxygenation device, the INSPIRA™ ART100, for FDA approval and plans to submit the HYLA™ blood sensor for FDA clearance later this year. The company has also signed pre-conditional summary distribution agreements totaling up to $546 million, subject to the completion of product development and regulatory approvals.
CustomersPartnersManagement Changes
growth-positive
Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100
Inspira Technologies has submitted its INSPIRA ART100 for approval under the Israeli Ministry of Healths AMAR regulation, which could open up new markets in Southeast Asia and South America. The INSPIRA ART100 is an innovative Augmented Respiration Technology designed to treat patients without mechanical ventilation while awake. The companys shares have surged 48.1% in the past year, compared to the industrys 11.2% increase. The Global Respiratory Devices Market is projected to reach $35.58 billion by 2029, growing at a CAGR of 5.89%.
CustomersExpand
growth-positive
Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets
Inspira Technologies, a medical technology company, has announced the submission of its initial blood oxygenation device, the INSPIRA ART100, for approval by AMAR, the Israeli Ministry of Healths medical device regulation unit. This marks a significant step in Inspiras expansion into new markets, particularly Southeast Asia and South America. The device uses adaptive blood oxygenation technology to measure patients blood parameters in real-time and deliver the necessary oxygen volume directly into the blood. This technology is expected to reduce complications associated with traditional ventilation methods, shorten hospital stays, and potentially save lives.
CustomersExpand
growth-positive
Inspira Technologies (IINN) Releases Favorable Data on VORTX
Inspira Technologies has achieved a significant milestone with its orbiting blood oxygenation technology, VORTX, achieving 100% compliance with regulatory guidelines for blood oxygenation and carbon dioxide removal. This development is expected to replace traditional mechanical ventilators with a superior alternative. The technology eliminates the need for membrane fibers, reducing pressure differentials and high shear stress. The global Extracorporeal Membrane Oxygenation machine market is projected to grow from $529.74 million in 2021 to $876.17 million by 2030, driven by the increasing prevalence of cardiopulmonary illnesses and respiratory failures.
CustomersInvestment
growth-positive
Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator
Inspira™Technologies OXY B.H.N. Ltd. has announced a significant technological breakthrough with its VORTX™ device, which has met 100% of regulatory guideline requirements for blood oxygenation and carbon dioxide removal at various blood flow rates. The devices pressure gradient remains at zero, which is associated with less damage to blood components. The company believes this technology will shift the industry away from fiber membrane-based devices, reducing manufacturing costs and eliminating global dependence on a single raw material supplier. The companys products have not yet been tested or used in humans and have not been approved by any regulatory entity.
Investment
growth-positive
Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days
Inspira Technologies OXY B.H.N. Ltd. has announced a major milestone in its proprietary technology to oxygenate blood for the INSPIRA ART (Gen 2). The company believes this technology will be a game-changer in the medical device market. The companys President, Joe Hayon, presented key highlights and announced the companys next major milestone. The INSPIRA ART (Gen 2) is designed to deliver oxygen straight into the blood. The company plans to announce the primary results of the core blood oxygenation technology of the INSPIRA ART (Gen 2) soon. The company also anticipates FDA Clearance for INSPIRA ART100 (Gen 1) in the first half of 2024.
InvestmentExpand
Growth-Positive
Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone
Inspira™ Technologies OXY B.H.N. Ltd., a medical technology company, announced that its President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the companys next major milestone. The conference call is scheduled for 9:00am Eastern Time on Monday, March 4, 2024. The company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels, potentially allowing patients to remain awake during treatment while reducing the need for invasive, risky, and costly mechanical ventilation systems.
growth-positive
Inspira™ Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements
Inspira Technologies, a medical technology company, is progressing towards 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its INSPIRA ART100 in the first half of 2024. The company also plans additional FDA 510(k) submissions for the HYLA blood sensor in 2024 and for INSPIRA ART disposables in 2025. Three patents have been approved by the United States Patent and Trademark Office (USPTO) and three more are pending. The company has signed $546 million in pre-conditioned summary distribution agreements, subject to regulatory approvals. The INSPIRA ART device is designed to continuously scan blood parameters in real-time to deliver the needed oxygen volume straight into the blood.
CustomersPartnersInvestment
growth-positive
Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies
Inspira Technologies, a medical technology company, has developed an in-house capability to simulate arterial and venous blood parameters of patients with specific medical conditions, eliminating the need for in vivo animal testing. This platform will advance the development of the companys HYLA Blood Sensor and VORTX Orbiting blood oxygenation delivery system. The technology allows for real-time management of blood parameters and can simulate a patients oxygen-deficient and carbon dioxide-rich blood. The company believes this will enable faster and more cost-effective research expansion.
InvestmentExpand
growth-positive
15 Hot Penny Stocks On the Move
The article discusses the performance of various penny stocks that have shown significant growth over the past month. These include Rigetti Computing Inc, MicroAlgo Inc, Lexicon Pharmaceuticals Inc, Inspira Technologies Oxy BHN Ltd, Hyliion Holdings Corp, Jumia Technologies AG - ADR, Canaan Inc - ADR, BioXcel Therapeutics Inc, D-Wave Quantum Inc, and SoundHound AI Inc. The article also mentions the views of economists and analysts who believe that the US economy might avoid a recession, with UBS and Goldman Sachs recently increasing their 2024 targets for the S&P 500.
Investment
growth-positive
Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System
Inspira Technologies, a medical technology company, has received the first ever U.S. Patent approval for an orbiting blood oxygenation delivery system, a core technology of the INSPIRA ART500 device. This innovation is expected to revolutionize the medical landscape and target the $19 billion mechanical ventilation market. The INSPIRA ART500 is a breakthrough device designed to empower breathing in patients by continuously measuring the patients blood parameters in real-time and delivering needed oxygen volume straight into the blood. The companys CEO, Dagi Ben-Noon, believes this is a monumental advancement in the landscape of blood oxygenation technologies.
CustomersInvestment
Growth-Positive
Inspira™ Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA™ ART Device
Inspira Technologies OXY BHN Ltd., a pioneer in life support technology, has signed a non-binding Letter of Intent (LOI) with Shamir Medical Center in Israel. The LOI is to assess the integration and performance of the INSPIRA™ ART100 device within Shamir Medical Centers clinical environment. The evaluation will be led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at Shamir Medical Center. The progression of this LOI hinges on the AMAR (medical devices and accessories) approval by the Israeli Ministry of Health for the Device, and the subsequent formalization of a detailed definitive evaluation agreement between the parties.
Partners
growth-positive
Inspira™ Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 INSPIRA™ ART Devices
Inspira Technologies has announced a summary distribution agreement with Glo-Med Networks. Under the agreement, Glo-Med will act as the distributor for Inspira Technologies devices in Saudi Arabia, United Arab Emirates, and Bahrain. The agreement is subject to regulatory approvals and will potentially provide Inspira Technologies with $32.6 million over a 5-year period. The deal is part of Saudi Arabias strategy to invest $65 billion and further privatize its healthcare sector. The agreement will be followed by a more comprehensive agreement.
PartnersExpand
growth-positive
Inspira™ Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for a New Disposable Perfusion Market Opportunity
Inspira Technologies, a pioneer in life support technology, has announced its plan to launch a single-use disposable blood oxygenation kit for its INSPIRA ART medical device series. The kit, which is currently in development, is also intended to be compatible with various other life support machines. The company aims to submit the kit for US FDA authorization in 2025. The launch of the kit is part of Inspiras strategy to potentially reduce hospital costs and expand its market presence.
CustomersExpand
growth-positive
Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device
Inspira Technologies, a pioneer in life support technology, has announced a non-binding Letter of Intent (LOI) with Northwestern Memorial Hospital in Chicago, Illinois. The LOI expresses the mutual interest to explore potential collaboration regarding the evaluation of how the INSPIRA ART100 device aligns with Northwesterns needs in clinical scenarios, workflow efficiency, and healthcare delivery. Northwestern will also agree to purchase all necessary disposables to operate the Devices and will, in turn, provide Inspira Technologies with valuable data and Device diagnostics from its usage. The terms of the agreement are subject to U.S. FDA clearance of the Device in the first half of 2024.
PartnersExpand
Growth-Positive
Inspira™ Technologies Closes on $3.88 Million Registered Direct Offering
Inspira Technologies OXY BHN Ltd. has announced the closing of its registered direct offering of over 3 million ordinary shares at a purchase price of $1.28 per share. The company also issued warrants to purchase up to an aggregate of the same number of ordinary shares at the same price. The warrants are exercisable immediately and will expire three and a half years after the closing date. The gross proceeds from the offering were approximately $3.88 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Investment
Growth-Positive
Inspira Announces $3.88 Million Registered Direct Offering
Inspira Technologies, a pioneer in life support technology, has announced a definitive agreement for the issuance and sale of over 3 million ordinary shares at a purchase price of $1.28 per share in a registered direct offering. The company will also issue unregistered warrants to purchase up to an aggregate of 3,031,250 ordinary shares. The offering is expected to close on or about December 28, 2023. The gross proceeds to Inspira from the offering are expected to be $3.88 million, which will be used for working capital and general corporate purposes.
Investment
growth-positive
Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024
Inspira Technologies, a pioneer in life support technology, has announced a significant advancement in its sensor technology. The new technology achieves 95% accuracy compared to standard blood gas analyzers and offers continuous, real-time blood monitoring capabilities. This development marks Inspiras potential entry into the disposables market. The first variant of this technology, HYLA™, is expected to be submitted under a 510(k) pathway with the U.S. Food & Drug Administration (FDA) in the second half of 2024. The technology is set to transform ICU operations by offering continuous, real-time blood data collection and analysis.
CustomersPartners
Growth-Positive
Inspira Technologies to Participate in J.P. Morgan Healthcare Conference
Inspira Technologies OXY BHN Ltd. announced that its CEO and President will attend the 42nd Annual J.P. Morgan Healthcare Conference in January 2024. The companys leaders are scheduled to meet with medical device and strategic consulting companies ahead of the expected FDA clearance of Inspiras life support device that directly oxygenates blood. The company is targeting to lead the way in transforming life-support care with its innovative solutions. The integration of these technologies signifies the potential to enhance patient outcomes and streamline hospital operations.
Management ChangesExpand
growth-positive
In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board
Inspira Technologies, a pioneer in life support technology, has announced the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a specialist in cardiac surgery and intensive care medicine and his expertise is expected to contribute significantly to the deployment of the INSPIRA™ ART100. The company expects to receive FDA approval for the INSPIRA™ ART100 in the first half of 2024. The appointment is seen as a strategic step towards accelerating the companys technologys time-to-market.
Management Changes
growth-positive
Inspira (IINN) Expands in Life Support Space With New Deal
Inspira Technologies OXY IINN has entered into a partnership with Ennocure MedTech to integrate bio-electronic technology into Inspiras INSPIRA ART, a novel approach to oxygenating blood as a replacement for traditional mechanical ventilation. The collaboration aims to address the global healthcare challenge of bloodstream infections linked to intravenous lines, which result in extended hospital stays and increased healthcare costs. Inspira plans to incorporate Ennocures bio-electronic technology into its INSPIRA ART to create a preventive approach to reduce complications and fight bloodstream infections.
Partners
growth-positive
Inspira Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients
Inspira Technologies OXY B.H.N. Ltd. has announced a partnership with Ennocure MedTech Ltd. to develop a bio-electronic treatment to prevent bloodstream infections in ICU patients. The treatment is part of Inspiras mission to oxygenate blood directly, replacing life support mechanical ventilation. The partnership aims to integrate Ennocures infection prevention solutions with Inspiras technology, potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. The collaboration is expected to accelerate the development and broaden the implementation of Inspiras advanced technology.
PartnersExpand
growth-positive
Inspira™ Technologies Reports Third Quarter 2023 Financial Results
Inspira Technologies, a pioneer in acute respiratory care, has announced its financial results for Q3 2023. The company has made progress in developing its novel technology for oxygenating blood, an alternative to traditional mechanical ventilation for respiratory patients. The technology has been bolstered by a grant from the Israeli Innovation Authority and new U.S. patents. The company is preparing for FDA approval of its ART100 device and has secured significant distribution agreements in Europe and Central America. The companys net loss for the nine months ended September 30, 2023, was $8.28 million.
InvestmentExpand
growth-positive
Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology
Inspira Technologies, a company focused on transforming the acute respiratory care market, has received a grant from the Israeli Innovation Authority (IIA) for its VORTX Disposable Blood Oxygenator Technology. The VORTX technology is being designed for compatibility with the INSPIRA ART Device line of products and is expected to address a $4 billion perfusion disposable market within the medical devices and applications sector. The IIA has committed to supporting the VORTX development project by granting funds equal to 40% of the first-year IIA approved budget of $1 million.
Investment
growth-positive
Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device
Inspira Technologies OXY BHN Ltd., a company focused on advancing acute respiratory care, has been granted an additional patent by the U.S. Patent and Trademark Office for its respiratory medical device, the INSPIRA ART500. The patent relates to a novel automated self-priming module designed for the device, which is aimed at ensuring patient safety and reducing the risks of clot formation. The company plans to enter the estimated $20 billion market with global deployments of its device. The company has also initiated patent applications in Europe and several other countries.
Investment
Neutral
Inspira™ Terminates ATM Program and Provides an Update
Inspira Technologies, a company focused on advancing acute respiratory care, has announced the termination of its at-the-market (ATM) equity offering program, effective immediately. The company also reassures stakeholders that its operations remain unaffected by the ongoing war involving the State of Israel and Hamas. Inspiras workforce, customers, suppliers, and production facilities are currently insulated from the impact of the war. The companys primary objective is the development of medical technologies and products aimed at preventing the necessity of mechanical ventilation.
CustomersPartners
growth-positive
Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP
Inspira Technologies, a company focused on acute respiratory care, has signed a distribution agreement with CIO MED GROUP, a leading medical devices distributor in Central America. The agreement is expected to generate $28 million in recurring revenues from disposable kits over five years, subject to regulatory approval. The partnership will focus on marketing and deploying the INSPIRA ART device line and disposable kits in Central America. The INSPIRA ART100, a cardio-pulmonary bypass device, was recently submitted for FDA clearance with an expected approval timeline of approximately six months.
PartnersExpand
growth-positive
Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World's Largest Extracorporeal Life Support Conference
Inspira Technologies, a company focused on revolutionizing acute respiratory care, has announced the unveiling of its INSPIRA ART line at the Extracorporeal Life Support Organization (ELSO) Conference. The INSPIRA ART medical device line includes the INSPIRA ART100, a cardio-pulmonary bypass (CPB) device, and the INSPIRA ART500, a device designed to provide acute respiratory support. The INSPIRA ART100 is expected to receive FDA clearance in the first half of 2024. Inspira has also entered into a collaboration with Perfusion Solution, Inc., a leading U.S. based company that provides a platform of advanced medical devices.
CustomersPartners
growth-positive
Inspira™ Announces 510(k) FDA Submission of INSPIRA™ ART100 Towards Commercialization
Inspira Technologies has submitted its INSPIRA ART 100, a cardio-pulmonary bypass device, to the U.S. Food and Drug Administration (FDA) via the 510(k) pathway. The company expects potential clearance during the first half of 2024. The device aims to transform external breathing assistance for over 20 million patients each year that require ventilation and oxygenation via external mechanical ventilation machinery. The company is preparing for global deployments of the INSPIRA ART100 systems once FDA clearance is achieved.
InvestmentExpand
growth-positive
Inspira (IINN) Advances Foothold in Europe With Extended Deal
Inspira Technologies has announced an extended service agreement with Innovimed to support clinical trials of its INSPIRA ART medical devices in the European Union. This agreement enhances Inspiras market presence and solidifies its foothold in the growing respiratory care landscape. The collaboration with Innovimed provides operational excellence and market insights, enabling Inspira to navigate the regulatory and operational landscape of the European Union. Inspiras medical devices aim to transform acute respiratory care by addressing critical shortcomings of existing technologies. The global acute respiratory distress syndrome (ARDS) market is projected to reach $2.1 billion by 2030, driving the demand for ARDS treatments. Inspira currently carries a Zacks Rank #3 (Hold).
PartnersCustomers
growth-positive
Inspira™ Signs Agreement Expansion with Innovimed for Clinical Trials of INSPIRA™ ART Respiratory Medical Devices
Inspira Technologies OXY B.H.N. Ltd. has signed a further Service Agreement with Innovimed for planned clinical trials of the INSPIRA™ ART medical devices. The extended agreement covers any European country. The company has also signed distribution agreements with Innovimed in Poland, Czech Republic, and Slovakia, potentially generating over $130 million in revenues for the Company over seven years. The medical devices aim to reduce mortality rates and the risk of complications associated with invasive mechanical ventilation systems. The CEO believes that this agreement will help make Inspiras technology well-recognized in the European Union.
Partners
Inspira™ Technologies Reports Second Quarter 2023 Financial Results
growth-positive
INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.
Inspira Technologies, a company focused on revolutionizing acute respiratory care, has completed a Usability Study for its INSPIRA ART100 device in Boston, Massachusetts. The study involved U.S. healthcare professionals who tested and examined the device in a setting designed to consider human factors. The INSPIRA ART100 is a medical device designed for cardiac and pulmonary support, providing continuous enrichment of the blood with oxygen and carbon dioxide removal. The device may be suitable for a wide range of extracorporeal treatments in the ICU and during heart surgery.
CustomersExpand
growth-positive
Inspira™ Technologies Receives Certification of Medical Devices Quality Management Systems, Another Step Towards EU Regulatory Approval
Inspira Technologies, a company focused on revolutionizing acute respiratory care, has received the ISO 13485:2016 Standard Certification. This certification is the international standard for quality management systems within the medical device industry and is a requirement for EU regulatory approval. The certification process involved a comprehensive evaluation of the companys quality management system, including documentation, risk management, and continuous improvement practices. The assessment was conducted by the British Standards Institution Group.
Customers
growth-positive
Inspira™ Technologies Enters into Collaboration Agreement with U.S.-Based Perfusion Solution Inc.
Inspira Technologies, a company focused on revolutionizing acute respiratory care, has announced a collaboration with Perfusion Solution, Inc., a leading provider of advanced medical devices, training, and staffing to U.S. hospitals. The collaboration will combine Inspiras INSPIRA ART100 product with Perfusion Solutions commercial infrastructure across the U.S. The INSPIRA ART100 is a blood circulation device that provides cardio-pulmonary support to patients undergoing or recovering from open-heart surgery. The collaboration is expected to facilitate the future commercialization of the INSPIRA ART100 following regulatory clearance.
Partners
growth-positive
Inspira™ Technologies Unveils Investor Deck Showcasing Revolutionary Advancement in Acute Respiratory Care
Inspira Technologies OXY B.H.N. Ltd. has released an investor deck highlighting their vision, achievements, and projected targets. The deck showcases their cutting-edge extracorporeal blood circulation medical devices, including the INSPIRA™ ART500, which uses INSPIRA™ AI to provide respiratory support without the use of lungs. The company aims to prevent the need for mechanical ventilators and improve patient care. They also plan to expand into a $20 billion total addressable market and secure additional patent grants. The investor deck is available on their website for interested parties. Inspira Technologies is an innovative medical technology company in the respiratory treatment arena.
InvestmentPartners
growth-positive
Inspira Technologies Appoints Dr. Nir as Chief Medical Officer
Inspira Technologies has appointed Dr. Adi Rizansky Nir as Chief Medical Officer. Dr. Nir will oversee and guide the companys medical operations and strategic initiatives. With her expertise and leadership skills, the company believes she will strengthen their commitment to delivering high-quality care and advancing their mission of improving treatments for Acute Respiratory Care. Dr. Nirs appointment is key to advancing potential regulatory approval and clinical adoption of their products. Inspira Technologies is an innovative medical technology company in the respiratory treatment arena, focused on developing a breakthrough Augmented Respiration Technology. The companys products have not yet been tested or used in humans and have not been approved by any regulatory entity.
Management Changes
growth-negative
Inspira™ Technologies Reports First Quarter 2023 Financial Results
Inspira Technologies OXY B.H.N. Ltd., a company aiming to revolutionize acute respiratory care, announced its financial results for the first quarter of 2023. The company reported a net loss of $3.0 million for the quarter, compared to a net loss of $1.3 million for the same period in 2022. Inspira Technologies also highlighted the progress of its devices, including the New ALICE Device and the HYLATM non-invasive blood sensor. Additionally, the company announced the development of the VORTX Blood Oxygenator, a disposable oxygenator unit, and the approval of a patent for its INSPIRA ART Systems Convertible Dual Lumen Cannula Device. Inspira Technologies had $11.5 million in cash, cash equivalents, and short-term bank deposits as of March 31, 2023.
InvestmentExpand
growth-positive
Inspira™ Technologies will Reveal the New ALICE™ Device at the World's Largest Extracorporeal Life Support Conference
Inspira Technologies will reveal the new ALICE device at the 34th Annual ELSO Conference. The ALICE device is an extracorporeal blood circulation medical device designed to provide cardiac and pulmonary support. Inspira Technologies plans to initiate commercial engagements at the conference and submit the ALICE device to the FDA for approval. The company aims to revolutionize acute respiratory care with its breakthrough Augmented Respiration Technology. Inspira Technologies is a growth-positive medical technology company.
PartnersInvestment
growth-positive
Inspira™ Technologies is Developing the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide
Inspira Technologies has announced the development of the VORTX Blood Oxygenator, a new technology aimed at revolutionizing acute respiratory care. The blood oxygenator, currently under development, has the potential to disrupt the perfusionists systems market, which is valued at $1.16 billion. The technology is designed to improve hemodynamic performance and reduce oxygenator failure, addressing the limitations of current hollow fiber membrane technology. The VORTX Blood Oxygenator will be submitted to the FDA for regulatory review and approval. Inspira Technologies is an innovative medical technology company focused on respiratory treatment. The companys products have not yet been tested or used in humans and have not been approved by any regulatory entity.
CustomersInvestment
Inspira Technologies and Genius Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
growth-positive
Inspira(TM) Technologies to Present at the Planet MicroCap Showcase 2023 on Wednesday, April 26, 2023 in Las Vegas
Inspira Technologies OXY B.H.N. Ltd. will present at the 2023 Planet MicroCap Showcase in Las Vegas. The company aims to revolutionize acute respiratory care with its breakthrough Augmented Respiration Technology. The technology allows patients to remain awake during treatment and reduces the need for invasive mechanical ventilation systems. Inspira Technologies products have not yet been tested in humans or approved by regulatory entities. The presentation will be available via webcast.
Partners
Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV
Inspira™ Technologies Reports Fourth Quarter 2022 and Full Year Financial Results
growth-positive
Inspira™ Technologies Announces First in Human of HYLA™ Blood Sensor in Clinical Study
Inspira Technologies has announced the first use of its HYLA Blood sensor in a patient undergoing open-heart surgery at Sheba Medical Center in Israel. The HYLA sensor is a non-invasive optical blood sensor that measures blood key parameters in real-time during extracorporeal procedures. The company is conducting a research clinical study to compare the HYLA sensors measurements to a standard blood gas analyzer. Inspira Technologies is an innovative medical technology company focused on respiratory treatment. The companys products have not yet been tested or used in humans and have not been approved by any regulatory entity.
Customers
growth-positive
Inspira™ Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA™ Blood Sensor
Inspira Technologies has received approval to conduct a clinical study of its HYLA blood sensor in patients undergoing open-heart surgery. The study aims to assess the correlation of blood parameters measured by the sensor versus a standard blood gas analyzer. The HYLA blood sensor, when integrated into the INSPIRA ART system or ALICE Device, will provide continuous key blood measurements in real-time, potentially improving patient outcomes and reducing complications. Inspira Technologies is an innovative medical technology company in the respiratory treatment arena.
Customers
Inspira™ Technologies Granted Patent by U.S. Patent Office for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use
Diamond Equity Research Initiates Coverage on Inspira Technologies Ltd. (NASDAQ: IINN)
Inspira™ Technologies Signs Strategic OEM Agreement with Terumo Cardiovascular
Inspira(TM) Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
growth-positive
Inspira™ Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report®
RedChip Companies will air an interview with Inspira Technologies, a groundbreaking respiratory support technology company, on The RedChip Money Report on Bloomberg TV. The interview discusses how Inspiras technology could reduce the need for invasive mechanical ventilation and become the new potential standard of care for acute respiratory failure. Inspira Technologies is an innovative medical technology company researching and developing a breakthrough Augmented Respiration Technology. The companys products have not yet been tested or used in humans and have not been approved by any regulatory entity.
Partners
Inspira™ Technologies Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission
growth-positive
Inspira™ Technologies Signs Agreement to Conduct Clinical Study of HYLA™ Blood Sensor
Inspira Technologies has signed an agreement with Sheba Medical Center in Israel to conduct a clinical study of the HYLA blood sensor. The study aims to evaluate the sensors capabilities to measure blood gases in a non-invasive and continuous manner. Sheba Medical Center is known for its medical research and collaboration with the MedTech industry. The agreement with Sheba Medical Center indicates their interest in Inspira Technologies blood sensor technology. The HYLA blood sensor is designed for multiple hospital settings and has the potential for commercial appeal as a standalone device. The study results are expected to contribute significantly to the products development. Inspira Technologies also plans to integrate the blood sensor into their INSPIRA ART system, which supports acute respiratory care. The clinical study is set to commence in the first quarter of 2023.
Partners
growth-positive
Inspira™ Technologies Reports Third Quarter 2022 Financial Results
Inspira Technologies, a respiratory support technology company, announced its financial results for Q3 2022. The company reported $16.2 million in cash, cash equivalents, and short-term bank deposits. It also highlighted its progress in research and development programs, including the commencement of a clinical study for its HYLA blood sensor. The company also announced strategic agreements in Europe and the U.S. for the deployment of its HYLA Blood Sensors, with potential values of $26.1 million and $59 million respectively. The companys net loss for the nine months ended September 30, 2022, was $7.1 million.
InvestmentPartners
growth-positive
Inspira™ Technologies Signs a Strategic Agreement in Europe to potentially provide $26.1 for Deployment of 1,364 HYLA™ Blood Sensors
Inspira Technologies has signed an exclusive distribution agreement for the HYLA Blood Sensor with Innovimed. The agreement is for a 5-year period and is subject to regulatory approvals. Innovimed will purchase a minimum order of 1,364 HYLA Blood Sensors and 128,511 disposable units for deployment in hospital units and operating theaters in Poland, Czech Republic, and Slovakia. The agreement is seen as a positive development in Inspiras strategy for market penetration in Europe. Inspira Technologies is an innovative medical technology company specializing in respiratory treatment.
Partners
Inspira™ Technologies Granted Patent by the Israeli Patent Office for Key Safety Component for the INSPIRA™ ART System
growth-positive
Inspira™ Technologies Develops a Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients - Potentially Targets $2.5 Billion ABG Market
Inspira Technologies has developed the HYLA blood sensor, a non-invasive optical sensor that aims to perform real-time and continuous blood monitoring without the need for actual blood samples. The sensor is designed to alert physicians of immediate signs of changes in a patients clinical condition. It is targeting the $2.5 billion Point of Care testing, ABG analyzer market. The HYLA blood sensor is expected to reduce the need for frequent invasive blood tests and can potentially save lives through real-time patient monitoring. Inspira Technologies is an innovative medical technology company specializing in respiratory treatment.
Customers
growth-positive
Inspira Technologies Has Listed an FDA Class I 510(k) Exempt component of the ART system
Inspira Technologies has listed a component of its ART and ECLS systems on the U.S. Food and Drug Administration Class I 510(k) exempt list. The component is intended to reduce complications associated with jugular vein cannula movement and can be used in the treatment of patients undergoing Extracorporeal Membrane Oxygenation (ECMO). The component is expected to allow safer mobilization for awake cannulated patients within and between hospitals and medical centers. Inspira Technologies is an innovative medical device company in the respiratory care industry.
Customers
growth-positive
Inspira™ Technologies Reveals Next Generation Liby™ System, an Extracorporeal Membrane Oxygenation System, Targeting a $531 Million Global ECMO Market
Inspira Technologies introduces the Liby System, an advanced form of life support for patients with heart and lung failure. The system is expected to target the $531 million global ECMO market and will be submitted to the FDA for approval in the first half of 2023. The Liby System is designed to be lightweight, durable, and equipped with long battery life for patient mobility. It also integrates the Companys non-invasive HYLA blood sensor technology for real-time patient monitoring. The system is expected to generate recurring revenues through consumable sales of its single-use disposable kit. Inspira Technologies aims to improve patient outcomes in over-crowded ICUs.
InvestmentCustomers
growth-positive
Inspira Technologies Announces Deployment Agreement in the Israeli Market to Target $15M
Inspira Technologies has announced a summary distribution agreement with Bepex Ltd., a leading Israeli medical technology company. The agreement includes the potential future deployment of Inspiras ART (Augmented Respiration Technology) systems, which aim to prevent the need for invasive mechanical ventilation. The collaboration with Bepex will initially focus on deploying the systems at major medical centers in Israel. This agreement follows three prior summary distribution agreements executed by Inspira, targeting approximately $386M in the U.S. and European markets. The agreement with Bepex has an initial term of seven years, subject to product development and regulatory approvals. The ART system is expected to become a new category of care for the acute respiratory failure market.
Partners
growth-positive
Inspira Technologies Signs a Strategic Agreement in the U.S. to Target $212 Million for Inspira Over a 7-Year Period, Subject to Regulatory Approvals
Inspira Technologies has signed an exclusive distribution agreement with Glo-Med Networks for the distribution of its respiratory support technology in 6 states in the United States. The agreement aims to meet the growing demand for innovative medical devices and related products. Glo-Med will purchase a minimum order of ART systems and disposable units for deployment at hospitals and medical centers. The agreement has an initial term of 7 years and will be followed by a more comprehensive agreement. Inspira Technologies sees this as an important milestone in penetrating the U.S. market. The ART system, designed to treat deteriorating respiratory failure patients, has the potential to minimize the need for invasive mechanical ventilation. Glo-Med Networks is excited to be the exclusive distributor for Inspira Technologies in the United States.
Partners
growth-positive
Inspira Technologies' "Artificial Lung" to Acquire a Digital Edge: The Company Contracted GlobalLogic, a Hitachi Group Company, for advanced digital product engineering services
Inspira Technologies has announced that its ART device brain will acquire an algorithm-enhanced digital platform through a partnership with GlobalLogic, a Hitachi Group Company. The brain of the ART device is an algorithm-enhanced control platform that manages the rebalancing of a patients oxygen saturation levels. The partnership with GlobalLogic aims to provide a more advanced digital experience for medical personnel. Inspira Technologies selected GlobalLogic for its experience in working with regulated industries such as medical device and pharmaceutical companies. Inspira Technologies is an innovative medical device company in the respiratory care industry, developing the ART device as an Artificial Lung for respiratory patients. The companys product has not yet been tested or approved by the FDA.
Partners
growth-positive
Inspira Technologies Reached Important Milestone as It Completed a Pump Bench Study
Inspira Technologies has successfully completed a pump bench study for its ART device, an early extracorporeal respiratory support system. The study compared Inspiras proprietary pump to other leading centrifugal pumps and assessed hemolysis in continuous flow blood pumps. The results of the study are an important milestone for the company as it progresses towards the manufacturing phase. Inspira Technologies aims to develop respiratory support technologies that allow patients to remain awake during treatment and minimize the use of invasive mechanical ventilation systems. The companys product has not yet been tested or used in humans and has not been approved by the FDA.
InvestmentExpand
growth-positive
Inspira Technologies and Ben-Gurion University Have Developed a Platform Designed to Prevent Blood Clotting in Inspira's ART System
Inspira Technologies has completed a development relating to the potential prevention of blood clotting when used with its Augmented Respiration Technology (ART) system. The company aims to extend the life of oxidizers and potentially prevent blood clotting through its ART system. The development was done in collaboration with Ben-Gurion University. Inspira Technologies is an innovative medical technology company in the respiratory treatment arena, and its ART technology potentially allows patients to remain awake during treatment while minimizing the use of mechanical ventilation systems. The companys products have not yet been tested or used in humans and have not been approved by the FDA.
PartnersInvestment
growth-positive
Inspira Technologies OXY B.H.N. Ltd Announces Closing of Initial Public Offering
Inspira Technologies has closed its initial public offering, raising approximately $16 million. The offering consisted of 2,909,091 units priced at $5.51 per unit, each consisting of one ordinary share and one warrant to purchase one ordinary share. Aegis Capital Corp. acted as the sole book-running manager for the offering. The ordinary shares and warrants are now trading on The Nasdaq Capital Market under the symbols IINN and IINNW, respectively. Inspira Technologies is a specialty medical device company focused on respiratory support technology. Its proprietary Augmented Respiration Technology aims to elevate and stabilize patient oxygen saturation levels, potentially reducing the need for invasive mechanical ventilation systems. The companys product has not yet been tested or approved by the FDA.
Public Trading
growth-positive
Inspira Technologies OXY B.H.N. Ltd Announces Pricing of Initial Public Offering
Inspira Technologies OXY B.H.N. Ltd, a specialty medical device company, has announced the pricing of its initial public offering (IPO) of 2,909,091 common units at a combined public offering price of $5.51. The gross proceeds of the offering are expected to be $16 million. The offering is expected to close on July 16, 2021. Aegis Capital Corp. is acting as the sole book-running manager for the offering. The ordinary shares and common warrants are expected to begin trading on The Nasdaq Capital Market on July 14, 2021.
Public Trading
growth-positive
Q&A: An intelligent oxygenation system that could eliminate need for ventilators
Med-Tech Innovation News interviewed Dagi Ben-Noon, CEO of Inspira Technologies, about their intelligent oxygenating system that aims to eliminate the need for ventilators. The system, called ART-500, offers a treatment for blood oxygenation and increasing oxygen saturation levels within 60 seconds, all while the patient is awake and responsive. It prevents the risks associated with mechanical ventilation and is minimally invasive. The system has been designed for ease of use and includes a plug-and-play cartridge. Inspira Technologies has developed the ART technology to provide a safe and easily administered treatment for respiratory failure. The company believes there is a real need in the market for their solution, especially in light of the complications and risks associated with mechanical ventilators during the COVID-19 pandemic.
Customers
growth-positive
הקורונה מטיסה את שאיפות ההנפקה של אינספירה
Israeli company Inspira Technologies is planning to raise $50 million in an initial public offering (IPO) on the NASDAQ, aiming for a valuation of $150 million. The company, which has developed a device for oxygenating blood that could reduce the need for ventilators, has announced a partnership with Sheba Hospital to test the device. The companys fundraising goal is to bring the product to market, estimated to cost $15 million, and use the remaining funds to establish infrastructure in Israel and abroad, primarily in the US, for production, distribution, further development, research, and partnerships with hospitals worldwide.
InvestmentPublic TradingPartners
growth-positive
Inspira Technologies Files U.S. Patent Application for its Innovative Respiratory Support Technology;Engages Leading U.S. Investment Bank for NASDAQ Listing
Inspira Technologies has filed a patent application for its new blood oxygenation system, the AXT, which eliminates the need for invasive mechanical ventilation. The system prevents the need for intubation and medically induced comas used for traditional mechanical ventilation, expanding respiratory support use beyond ICUs. The patent grants Inspira the exclusive ability to make a product designed to prevent the need for mechanical ventilation. The company aims to increase the accessibility of efficient and effective respiratory support for patients worldwide. The technology lowers the risks and costs of existing ventilation systems and allows patients to remain awake and mobile during treatment. Inspira Technologies is an innovative medical technology company in the respiratory support space.
CustomersExpand
Inspira Technologies Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 45 |
| Team members | 10 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Inspira Technologies Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 515806495 |
| Crunchbase | insense-medical |
| Phone | +97299664488 |
| Creator | Hilla Gorokhovsky |
| Creator email | hilla.gorokhovsky@sncentral.org |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-05-05T00:00:00.000Z |
| Created | 2019-04-23T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NASDAQ on Jul, 2021<br> |